<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="pmc-domain-id">2403</journal-id><journal-id journal-id-type="pmc-domain">jimmres</journal-id><journal-id journal-id-type="publisher-id">jir</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12014272</article-id><article-id pub-id-type="pmcid-ver">PMC12014272.1</article-id><article-id pub-id-type="pmcaid">12014272</article-id><article-id pub-id-type="pmcaiid">12014272</article-id><article-id pub-id-type="pmid">40265107</article-id><article-id pub-id-type="doi">10.1155/jimr/6348238</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>In Silico Design and Characterization of a Multiepitope Vaccine Candidate Against <italic toggle="yes">Brucella canis</italic> Using a Reverse Vaccinology Approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Arriagada</surname><given-names initials="V">Vicente</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Osorio</surname><given-names initials="A">Alberto</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carrera-Naipil</surname><given-names initials="C">Crisleri</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Villacis-Aguirre</surname><given-names initials="CA">Carlos A.</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Escobar</surname><given-names initials="C">Cristian</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morales</surname><given-names initials="N">Nicol&#225;s</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Villa</surname><given-names initials="D">Danthe</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mardones</surname><given-names initials="L">Lien</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>P&#233;rez</surname><given-names initials="D">Dafne</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jara</surname><given-names initials="M">Macarena</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Molina</surname><given-names initials="RE">Ra&#250;l E.</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferrari</surname><given-names initials="&#xCD;">&#205;talo</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Azocar</surname><given-names initials="S">Sebasti&#225;n</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names initials="LA">Leonardo A.</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4358-1015</contrib-id><name name-style="western"><surname>O&#241;ate</surname><given-names initials="&#xC1;A">&#193;ngel A.</given-names></name><email>aonate@udec.cl</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Laboratory of Molecular Immunology, Department of Microbiology, Faculty of Biological Sciences, University of Concepci&#243;n, Concepci&#243;n, Chile</aff><aff id="I2">
<sup>2</sup>Simes Educational Center, Santiago, Chile</aff><author-notes><fn fn-type="other"><p>Academic Editor: Baohui Xu</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2025</year></pub-date><volume>2025</volume><issue-id pub-id-type="pmc-issue-id">479661</issue-id><elocation-id>6348238</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>22</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-23 16:25:32.377"><day>23</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Vicente Arriagada et al. Journal of Immunology Research published by John Wiley &amp; Sons Ltd.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JIR2025-6348238.pdf"/><abstract><p>
<italic toggle="yes">Brucella canis</italic> is a Gram-negative bacterium that causes canine brucellosis, a zoonotic disease with serious implications for public health and the global economy. Currently, there is no effective preventive vaccine for <italic toggle="yes">B. canis</italic>. Control measures include diagnostic testing, isolation, and euthanasia of infected animals. However, these measures face significant limitations, such as diagnostic challenges, ethical concerns, and limited success in preventing transmission. Epidemiologically, canine brucellosis exhibits seroprevalence rates ranging from less than 1% to over 15%, with higher rates reported in stray dogs and regions of low socioeconomic development. This study employed a reverse vaccinology approach to design and characterize a multiepitope vaccine candidate against <italic toggle="yes">B. canis</italic>, aiming to prevent infection caused by this pathogen. A comprehensive in silico analysis of the complete <italic toggle="yes">B. canis</italic> proteome was conducted to identify proteins with potential as vaccine targets. Predicted epitopes for B and T cells were analyzed, and those with the highest capacity to elicit a robust immune response were selected. These proteins were classified as plasma membrane proteins, outer membrane proteins (OMPs), or proteins with similarity to virulence factors. Selection criteria emphasized their essential roles in bacterial function, lack of homology with proteins from dogs or mice, and presence of fewer than two transmembrane domains. From this process, four candidate proteins were identified. Epitopes for B and T cells within these proteins were predicted and analyzed, selecting the most immunogenic sequences. The overlap between B- and T-cell epitopes narrowed the selection to six final epitopes. These selected epitopes were then assembled into a multiepitope vaccine construct using flexible linkers to ensure structural integrity and molecular adjuvants to enhance immunogenicity. The physicochemical properties, antigenicity, and toxicity of the designed vaccine were evaluated. Additionally, the secondary and tertiary structure of the vaccine was predicted and refined, followed by a molecular interaction analysis with the Toll-like receptor 4 (TLR4) receptor. The designed vaccine proved to be highly antigenic, nonallergenic, and nontoxic. Validation of its secondary and tertiary structures, along with molecular docking analysis, revealed a high binding affinity to the TLR4 receptor. Molecular dynamics simulations and normal mode analysis further confirmed the vaccine's structural stability and binding capacity. A multiepitope vaccine candidate against <italic toggle="yes">B. canis</italic> was successfully designed and characterized using a reverse vaccinology approach. This vaccine construct is expected to induce robust humoral and cellular immune responses, potentially conferring protective immunity against <italic toggle="yes">B. canis</italic>. The results of this study are promising; however, in vitro and in vivo tests are necessary to validate the vaccine's protective efficacy. Furthermore, the described method could serve as a framework for developing vaccines against other pathogens.</p></abstract><funding-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100002850">Fondo Nacional de Desarrollo Cient&#237;fico y Tecnol&#243;gico</funding-source><award-id>1230018</award-id></award-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100006255">Universidad de Concepci&#243;n</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>
<italic toggle="yes">Brucella</italic> is a monophyletic genus of Gram-negative bacteria comprising at least 13 very similar species. These species exhibit minor genetic differences and display host specificity among several mammals [<xref rid="B1" ref-type="bibr">1</xref>]. These bacteria induce brucellosis, a prevalent zoonotic disease transferred among animals or from animals to people via direct contact with blood, urine, placenta or through the inhalation of infected aerosols [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. It is a priority disease for the World Organization for Animal Health (WOAH) due to its significant impact on public health, the economy, and global trade [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. This disease is one of the main causes of abortions and infertility in numerous animal species, which leads to great economic losses [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>], and human brucellosis remains the most common zoonotic disease worldwide, with more than 500,000 new cases annually [<xref rid="B8" ref-type="bibr">8</xref>]. In humans, exposure to brucellosis can cause acute inflammation in several infected organs, displaying irregular fever and flu-like symptoms [<xref rid="B9" ref-type="bibr">9</xref>]. The majority of brucellosis cases are caused by the most predominant <italic toggle="yes">Brucella</italic> species in livestock and humans: <italic toggle="yes">B. melitensis</italic>, <italic toggle="yes">B. abortus</italic>, and <italic toggle="yes">B. suis</italic> [<xref rid="B10" ref-type="bibr">10</xref>]; however, <italic toggle="yes">B. canis</italic>, the principal etiological agent of canine brucellosis [<xref rid="B11" ref-type="bibr">11</xref>] can also be transmitted to humans, causing a neglected and undervalued disease [<xref rid="B12" ref-type="bibr">12</xref>]. Canine brucellosis is characterized by a high seroprevalence worldwide in dogs and, consequently, a high likelihood of transmission to humans [<xref rid="B13" ref-type="bibr">13</xref>]. This disease is transmitted among dogs through genital contact, oronasal mucosae, and conjunctival tissues [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. It is considered a venereal infection when <italic toggle="yes">B. canis</italic> is shed in the semen of infected dogs, which can occur during the first weeks after infection or persist for years in these animals [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Additionally, infection with <italic toggle="yes">B. canis</italic> is associated with high neonatal mortality rates [<xref rid="B16" ref-type="bibr">16</xref>]. However, surviving infected puppies may become significant transmission sources, as they can be permanent carriers of the bacterium [<xref rid="B17" ref-type="bibr">17</xref>]. Although the host range of <italic toggle="yes">B. canis</italic> predominantly includes domestic dogs, specific antibodies against <italic toggle="yes">B. canis</italic> antigens have been detected in several mammal species. Experimental infections have also been recorded in goats, cattle, pigs, sheep, and chimpanzees using <italic toggle="yes">B. canis</italic> [<xref rid="B18" ref-type="bibr">18</xref>]. In humans, infection with this bacterium tends to produce nonspecific symptoms, similar to other <italic toggle="yes">Brucella</italic> infections, causing intermittent fever, fatigue, and lymphadenopathy [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. From an epidemiological perspective, <italic toggle="yes">B. canis</italic> seroprevalence rates in dogs range from less than 1% to 15% or higher, with elevated rates observed in stray dogs and impoverished areas. This is likely attributed to a higher proportion of intact dogs and uncontrolled breeding within these populations [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Moreover, <italic toggle="yes">B. canis</italic> infections in humans are often underdiagnosed due to their nonspecific symptoms [<xref rid="B21" ref-type="bibr">21</xref>]. Recently, a notable increase in canine brucellosis cases has been reported in Great Britain, raising concerns about its potential impact on human health [<xref rid="B22" ref-type="bibr">22</xref>]. This increase is alarming because there are currently no specific treatments or effective cures for this disease. Antibiotic therapy has shown limited success in controlling the infection, and when the primary goal is to prevent disease transmission in dogs, euthanasia remains the most reliable measure for both symptomatic and asymptomatic carriers [<xref rid="B23" ref-type="bibr">23</xref>]. Given these challenges&#8212;such as the close proximity of infected dogs to humans and the lack of effective therapies&#8212;there is an urgent need to develop preventive measures. Developing effective canine vaccines capable of eliciting a specific immune response against <italic toggle="yes">B. canis</italic> is a promising approach to controlling the disease in dogs and reducing its transmission to humans [<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B26" ref-type="bibr">26</xref>]. Protective immunity against <italic toggle="yes">B. canis</italic> should focus on developing of INF-<italic toggle="yes">&#947;</italic> secreting type-1 T helper cells (Th1), effectively responding to intracellular pathogens. This type of response must be induced by effective vaccines targeting this bacterium [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. Despite significant efforts in the field of <italic toggle="yes">Brucella</italic> vaccinology [<xref rid="B29" ref-type="bibr">29</xref>], studies specifically aimed at developing vaccines for canine brucellosis are limited and have been confined to the last decade [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. Notable experimental vaccines against <italic toggle="yes">B. canis</italic> include attenuated vaccines based on mutations in the <italic toggle="yes">vir</italic>B genes that encode the type IV secretion system (T4SS) of <italic toggle="yes">B. canis</italic>, or these based on recombinant proteins using outer membrane proteins (OMPs) such as Omp31 or recombinant VirB proteins [<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>]. Recently, a heterologous vaccine based on <italic toggle="yes">B. ovis</italic> mutant for ABC transporter (&#916;<italic toggle="yes">abcBA</italic>) has shown protection against <italic toggle="yes">B. canis</italic> challenge in mice [<xref rid="B34" ref-type="bibr">34</xref>]. Progress in genomes, proteomics, and bioinformatics is essential for identifying antigenic peptides from specific diseases, hence aiding in the design and manufacture of next-generation vaccines [<xref rid="B35" ref-type="bibr">35</xref>]. Initially, these analyses involved a filtering process of the proteome's total sequences to identify the pathogen's essential proteins, prioritizing those located subcellularly with potential antigenic, nonallergenic, and nontoxic epitopes for B cells and T cells to stimulate a safe and robust humoral and cellular immune response [<xref rid="B36" ref-type="bibr">36</xref>]. This approach has recently led to an increase in using bioinformatics tools to develop chimeric vaccines, selecting conserved or superimposed epitopes capable of generating specific B- and T-cell responses (CD4+ and CD8+) [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. Moreover, linker sequences, which are short amino acid sequences that separate epitopes, play a critical role in multiepitope vaccines by ensuring proper epitope processing and presentation by the host's immune system. This is achieved by preventing the formation of junctional epitopes, which could otherwise compromise the specificity of the immune response. Additionally, linkers contribute to the chimera's flexibility and structural integrity, preserving its overall stability and functionality as a vaccine candidate [<xref rid="B38" ref-type="bibr">38</xref>]. Proper placement of linkers can further enhance the immunogenicity of the epitopes, thereby improving the development of a robust and specific immune response [<xref rid="B39" ref-type="bibr">39</xref>]. Another crucial component of vaccine design is the use of adjuvants, which enhance the immune response to the target antigen. Classical adjuvants, such as aluminum salts or emulsions (e.g., Freund's adjuvant), function by stimulating the innate immune system and promoting antigen presentation to activate adaptive immunity. However, these adjuvants are often administered separately from the antigen, which may lead to limited effectiveness or side effects [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>]. In contrast, <italic toggle="yes">built-in adjuvants</italic> are genetically or chemically incorporated directly into the vaccine construct, allowing for a more targeted and synergistic enhancement of the immune response. These adjuvants can include specific immunostimulatory molecules, such as Toll-like receptor (TLR) agonists, cytokines, or other immune-enhancing domains, which are integrated into multiepitope vaccines to optimize immunogenicity [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>]. This approach ensures close spatial and temporal association between the antigenic epitopes and the adjuvant, improving vaccine efficacy while potentially reducing adverse effects.</p><p>Therefore, this study focuses on extracting and identifying immunogenic epitopes from the <italic toggle="yes">B. canis</italic> proteome to design a multiepitope canine vaccine candidate. The goal is to effectively stimulate B- and T-cell responses and confer robust protection against this pathogen.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><p>
<xref rid="fig1" ref-type="fig">Figure 1</xref> illustrates a flow diagram for the design of the multiepitope vaccine candidate against <italic toggle="yes">B. canis</italic>. This candidate's design required the use of a series of servers and programs described sequentially in the text. Table <xref rid="supplementary-material-1" ref-type="sec">S1</xref> provides a detailed list of the servers and databases used in the vaccine design, specifying their role or function in the study and their availability. Additionally, Table <xref rid="supplementary-material-1" ref-type="sec">S2</xref> presents the cutoff values applied in the different servers and programs used throughout the analysis.</p><sec id="sec2.1"><title>2.1. Search for Candidate Proteins</title><p>A representative <italic toggle="yes">Brucella canis</italic> RM6/66 strain genome (GCF_000740335.1) was retrieved from the NCBI GenBank database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/genbank" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/genbank</ext-link>) [<xref rid="B44" ref-type="bibr">44</xref>]. This sequence was analyzed using the PSORTb v.3.0.3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.psort.org/psortb/index.html" ext-link-type="uri">https://www.psort.org/psortb/index.html</ext-link>) server to identify the subcellular localization of proteins, which served as a basis for selecting proteins located in the outer membrane, periplasmic space, plasma membrane, and extracellular regions [<xref rid="B45" ref-type="bibr">45</xref>]. The next step involved selecting proteins homologous to known virulence factors as referenced in the Virulence Factors of Bacterial Pathogens Database (VFDB) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.mgc.ac.cn/VFs/main.htm" ext-link-type="uri">http://www.mgc.ac.cn/VFs/main.htm</ext-link>), using BLASTp [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>]. Essential proteins were selected, which refer to the genes that an organism needs to survive under certain specific conditions; this search was carried out through the Database of Essential Genes (DEG) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://origin.tubic.org/deg/public/index.php" ext-link-type="uri">http://origin.tubic.org/deg/public/index.php</ext-link>) [<xref rid="B48" ref-type="bibr">48</xref>]. The search also extended to identifying nonhomologous sequences to proteins specific to <italic toggle="yes">Canis familiaris</italic> (dogs) and <italic toggle="yes">Mus musculus</italic> (mice) as found in the NCBI database [<xref rid="B49" ref-type="bibr">49</xref>]. Proteins associated with virulence factors, identified as essential and nonhomologous to dogs and mice, were further analyzed for their antigenicity, presence of transmembrane domains, signal peptide, and topology using specialized servers: VaxiJen v2.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html" ext-link-type="uri">https://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html</ext-link>), ANTIGENpro (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scratch.proteomics.ics.uci.edu" ext-link-type="uri">https://scratch.proteomics.ics.uci.edu</ext-link>), TMHMM-2.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://services.healthtech.dtu.dk/services/TMHMM-2.0/" ext-link-type="uri">https://services.healthtech.dtu.dk/services/TMHMM-2.0/</ext-link>), and DeepTMHMM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dtu.biolib.com/DeepTMHMM" ext-link-type="uri">https://dtu.biolib.com/DeepTMHMM</ext-link>), respectively [<xref rid="B50" ref-type="bibr">50</xref>&#8211;<xref rid="B53" ref-type="bibr">53</xref>].</p></sec><sec id="sec2.2"><title>2.2. Prediction of Epitopes for B and T Cells</title><p>The proteins identified in the previous steps were used to predict B- and T-cell epitopes. Linear B-cell epitopes were predicted using the ABCPred server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://crdd.osdd.net/raghava/abcpred/" ext-link-type="uri">http://crdd.osdd.net/raghava/abcpred/</ext-link>) [<xref rid="B54" ref-type="bibr">54</xref>], while CD8<sup>+</sup> T cells MHC class I and CD4<sup>+</sup> T cells MHC class II epitopes were identified from the Immune Epitope Database (IEDB) analysis resource (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iedb.org" ext-link-type="uri">https://www.iedb.org</ext-link>) [<xref rid="B55" ref-type="bibr">55</xref>]. The binding of peptides to MHC class I molecules was predicted with the stabilized matrix method (SMM) [<xref rid="B56" ref-type="bibr">56</xref>], and for MHC class II molecules, the NetMHCIIpan 4.1 method was used [<xref rid="B57" ref-type="bibr">57</xref>]. The mouse H-2 reference allele set with an IC50 of less than 200&#8201;nM was applied [<xref rid="B58" ref-type="bibr">58</xref>]. Following this, the B- and T-cell epitopes were aligned using MEGA 11 software [<xref rid="B59" ref-type="bibr">59</xref>] to identify the overlapping epitopes for B, CD8<sup>+</sup>, and CD4<sup>+</sup> T cells, which are the focus of further analysis. The antigenicity of these peptides was assessed using ANTIGENpro [<xref rid="B52" ref-type="bibr">52</xref>], the allergenicity was predicted using AllerTOP2.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ddg-pharmfac.net/AllerTOP/" ext-link-type="uri">https://www.ddg-pharmfac.net/AllerTOP/</ext-link>) [<xref rid="B60" ref-type="bibr">60</xref>], the toxicity by ToxinPred2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://webs.iiitd.edu.in/raghava/toxinpred2/" ext-link-type="uri">https://webs.iiitd.edu.in/raghava/toxinpred2/</ext-link>) [<xref rid="B61" ref-type="bibr">61</xref>] and their potential to induce IFN-<italic toggle="yes">&#947;</italic> was evaluated through IFNepitope servers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://crdd.osdd.net/raghava/ifnepitope/" ext-link-type="uri">http://crdd.osdd.net/raghava/ifnepitope/</ext-link>) [<xref rid="B62" ref-type="bibr">62</xref>], respectively.</p></sec><sec id="sec2.3"><title>2.3. Design of the Multiepitope Vaccine</title><p>To develop the multiepitope chimeric vaccine, the chosen overlapping epitopes were connected using a GSGS flexible linker, with a CTB (a nontoxic component of the cholera toxin's B subunit) was used as an adjuvant sequence at the N-terminal end to boost immunogenicity. Cholera toxin subunit b as adjuvant increases antigenic presentation, B-cell differentiation, as well as cytokine production and their interaction with T cells [<xref rid="B63" ref-type="bibr">63</xref>], connected by an EAAAK rigid linker. Additionally, a TpD (an epitope known as a potent universal adjuvant for CD4 T-cell helper [<xref rid="B64" ref-type="bibr">64</xref>] sequence was attached at the C-terminal end of the chimeric protein via another GSGS flexible linker; connectors are crucial to prevent the binding among epitopes [<xref rid="B65" ref-type="bibr">65</xref>]. Therefore, increased flexibility allows for greater variation in distance between the N and C termini of the fusion protein, impacting antigenic presentation by effectively separating embedded domains of interest [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>]. Including lysine (K) in vaccine, constructs enhances solubility by avoiding B-cell epitopes and offers improved immune response while also providing a favorable cleavage site for proteases within lysosomes, an essential step in CD4 T-cell presentation [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>].</p></sec><sec id="sec2.4"><title>2.4. Antigenicity, Allergenicity, Toxicity, and Physicochemical Parameters</title><p>The antigenicity of this chimeric protein was evaluated using VaxiJen v2.0 [<xref rid="B50" ref-type="bibr">50</xref>] and ANTIGENpro [<xref rid="B52" ref-type="bibr">52</xref>] servers. Allergenicity predictions for the vaccine construct were made using the AllerTOP2.0 server [<xref rid="B60" ref-type="bibr">60</xref>], and toxicity assessments were carried out using the ToxinPred2 server [<xref rid="B61" ref-type="bibr">61</xref>]. Physicochemical parameters, such as theoretical isoelectric points, molecular weight, and hydrophilicity, were analyzed using the ProtParam server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://web.expasy.org/protparam/" ext-link-type="uri">https://web.expasy.org/protparam/</ext-link>) [<xref rid="B70" ref-type="bibr">70</xref>]. Lastly, the SOLpro server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scratch.proteomics.ics.uci.edu" ext-link-type="uri">https://scratch.proteomics.ics.uci.edu</ext-link>) was employed to predict the solubility propensity of the vaccine construct [<xref rid="B71" ref-type="bibr">71</xref>].</p></sec><sec id="sec2.5"><title>2.5. Secondary Structure and Intrinsic Disorder Analyses</title><p>To assess the structural integrity of the designed vaccine&#180;s peptide sequence, its secondary structure was determined using the PDBsum server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/" ext-link-type="uri">https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/</ext-link>) [<xref rid="B72" ref-type="bibr">72</xref>]. Additionally, intrinsic disorder was performed using IUPred3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://iupred3.elte.hu" ext-link-type="uri">https://iupred3.elte.hu</ext-link>), evaluating regions with a higher propensity for the structural disorder based on the amino acid composition [<xref rid="B73" ref-type="bibr">73</xref>].</p></sec><sec id="sec2.6"><title>2.6. Tertiary Structure Analysis and Validation</title><p>using the AlphaFold Server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://alphafoldserver.com" ext-link-type="uri">https://alphafoldserver.com</ext-link>) [<xref rid="B74" ref-type="bibr">74</xref>]. This model was then refined using the GalaxyRefine server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE" ext-link-type="uri">https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE</ext-link>) [<xref rid="B75" ref-type="bibr">75</xref>], which employed soft and aggressive relaxation methods, side chain reconstruction, and molecular dynamics simulation. Postrefinement, the vaccine's 3D structure was validated by ERRAT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.doe-mbi.ucla.edu/errat/" ext-link-type="uri">https://www.doe-mbi.ucla.edu/errat/</ext-link>), which analyzed the interactions with the environment [<xref rid="B76" ref-type="bibr">76</xref>], and by ProSA-web (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prosa.services.came.sbg.ac.at/prosa.php" ext-link-type="uri">https://prosa.services.came.sbg.ac.at/prosa.php</ext-link>) for energy analysis [<xref rid="B77" ref-type="bibr">77</xref>]. The model&#180;s geometry was evaluated using MolProbity (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://molprobity.biochem.duke.edu" ext-link-type="uri">http://molprobity.biochem.duke.edu</ext-link>) [<xref rid="B78" ref-type="bibr">78</xref>], and the stereochemical quality was assessed with the PROCHECK tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/thornton-srv/software/PROCHECK/" ext-link-type="uri">https://www.ebi.ac.uk/thornton-srv/software/PROCHECK/</ext-link>), generating a Ramachandran plot and Wiring Diagram to examine the incorporated residues &#8216;geometry within the vaccine structure [<xref rid="B79" ref-type="bibr">79</xref>].</p></sec><sec id="sec2.7"><title>2.7. Prediction of Discontinuous B-Cell Epitopes</title><p>Once the 3D protein structure model was refined, the discontinuous B-cell epitopes were predicted using the ElliPro antibody epitope prediction server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://tools.iedb.org/ellipro/" ext-link-type="uri">http://tools.iedb.org/ellipro/</ext-link>) [<xref rid="B80" ref-type="bibr">80</xref>]. This server uses algorithms based upon values of protrusion index (PI) values for measuring the PI of the residues, estimating the shape of the protein as an ellipsoid, and adjacent cluster residues [<xref rid="B81" ref-type="bibr">81</xref>]. The vaccine construct was uploaded in PDB format, and all default parameters were kept for epitope prediction.</p></sec><sec id="sec2.8"><title>2.8. Structural and Functional Characterization of Vaccine Construct: Engineering Disulfides, Signal Peptide, and Transmembrane Topology</title><p>Disulfide engineering introduces disulfide bonds between protein residues. These bonds are covalent interactions that increase the stability of the protein structure by decreasing conformational entropy [<xref rid="B82" ref-type="bibr">82</xref>]. Disulfide by Design 2 v2.13 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cptweb.cpt.wayne.edu/DbD2/" ext-link-type="uri">http://cptweb.cpt.wayne.edu/DbD2/</ext-link>) was used to disulfide engineer the 3D protein structure of the vaccine construct [<xref rid="B83" ref-type="bibr">83</xref>]. Residue pairs with an energy value lower than 2.2 kcal/mol and a <italic toggle="yes">&#967;</italic><sup>3</sup> angle between &#8211;87&#176; and +97&#176; within this range were chosen for disulfide bond formation, given that 90% of naturally formed disulfide bonds exhibit these characteristics [<xref rid="B84" ref-type="bibr">84</xref>]. Additionally, the signal peptide was predicted using the SignalP-6.0 server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://services.healthtech.dtu.dk/services/SignalP-6.0/" ext-link-type="uri">https://services.healthtech.dtu.dk/services/SignalP-6.0/</ext-link>), which detects five types of signal peptides through a machine-learning model [<xref rid="B85" ref-type="bibr">85</xref>]. The transmembrane topology was predicted using the DeepTMHMM server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dtu.biolib.com/DeepTMHMM" ext-link-type="uri">https://dtu.biolib.com/DeepTMHMM</ext-link>), which predicts and classifies protein topology [<xref rid="B53" ref-type="bibr">53</xref>].</p></sec><sec id="sec2.9"><title>2.9. Molecular Docking</title><p>Molecular docking was performed using ClusPro 2.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cluspro.bu.edu/login.php" ext-link-type="uri">https://cluspro.bu.edu/login.php</ext-link>), a fast rigid-body protein&#8211;protein docking server, to predict interactions with ligands such as the TLR4 [<xref rid="B86" ref-type="bibr">86</xref>]. The crystallized structure of the TLR4/MD-2/lipid IVa complex from <italic toggle="yes">M. musculus</italic> (PDB ID 3VQ1) [<xref rid="B87" ref-type="bibr">87</xref>] was retrieved from the RCSB Protein Data Bank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org" ext-link-type="uri">https://www.rcsb.org</ext-link>) [<xref rid="B88" ref-type="bibr">88</xref>]. We selected a TLR4 chain and MD-2 chains, which were manually extracted from the PDB file and then uploaded to the ClusPro 2.0 server for subsequent docking analysis. The resulting models were further refined using the CHARMM-GUI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.charmm-gui.org" ext-link-type="uri">https://www.charmm-gui.org</ext-link>) molecular mechanics package [<xref rid="B89" ref-type="bibr">89</xref>].</p></sec><sec id="sec2.10"><title>2.10. Normal Mode Analysis</title><p>Normal mode analyses were conducted on the free-form vaccine construct to describe the flexible states accessible to a protein about an equilibrium position, and for this purpose, we utilized a local deployment of the WEBnma3 API (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.cbu.uib.no/webnma3" ext-link-type="uri">https://apps.cbu.uib.no/webnma3</ext-link>) [<xref rid="B90" ref-type="bibr">90</xref>] to evaluate inter-residue correlations and to scrutinize potential conformational changes. This API applies elastic network models, offering a reliable and cost-effective computational method to analyze the vaccine construct. A single structure analysis was performed, and the workflow automatically calculated normal modes, average deformation energies, fluctuations and atomic displacement analysis, protein trajectories for specified modes, and correlation analysis, providing insight and validation into the dynamic properties of the vaccine construct.</p></sec><sec id="sec2.11"><title>2.11. Molecular Dynamic Simulations (MDSs)</title><p>MDSs were performed for the structural analysis of the refined construct both in its free form and complexed with TLR4/MD-2. The following procedures were executed for both types of analysis: (a) Ensemble preparation: The CHARMM-GUI server was used to generate a GROMACS input using its Solution Builder tool, with the TIP3P water model employed to fill the cubic space disposed for each experiment [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>]. Monte Carlo methods were applied to add K<sup>+</sup> and Cl<sup>&#8722;</sup> ions to each system until it reached the neutralization of the system. The system was described using the Amber Force Field ff19sb [<xref rid="B93" ref-type="bibr">93</xref>]. (b) Minimization: The system's potential energy was minimized using the steepest descent minimization algorithm. (c) Equilibration: The system was equilibrated using <italic toggle="yes">NVT</italic> and <italic toggle="yes">NpT</italic> ensembles targeted at 300K temperature and 1&#8201;bar pressure. (d) Production: The final MDS for each scenario was carried out for 30&#8201;ns, with an integration step of 2 fs, and energies were recorded every 10 ps. To measure the conformational stability of the vaccine construct and the vaccine-TLR4 complex forms post 30&#8201;ns simulations, root mean square deviation (RMSD) profiles for backbone residues, radius of gyration (Rgyr), and root mean square fluctuation (RMSF) from C-alpha atoms were analyzed.</p></sec><sec id="sec2.12"><title>2.12. Binding-Free Energy</title><p>The binding-free energies of the docked complex were estimated using the MM-PBSA method [<xref rid="B94" ref-type="bibr">94</xref>]. The gmx_MMPBSA tool was employed for these calculations [<xref rid="B95" ref-type="bibr">95</xref>]. For the binding energy analysis, 1000 frames were extracted at regular intervals from the simulation trajectories.</p></sec><sec id="sec2.13"><title>2.13. Codon Optimization and In Silico Cloning of the Vaccine Construct</title><p>Codon optimization is needed to improve the rate of expression of a foreign gene in the host organisms [<xref rid="B96" ref-type="bibr">96</xref>]. The tool EMBOSS Backtranseq (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/jdispatcher/st/emboss_backtranseq" ext-link-type="uri">https://www.ebi.ac.uk/jdispatcher/st/emboss_backtranseq</ext-link>) was used for reverse translation and codon optimization of the vaccine construct in <italic toggle="yes">E. coli</italic> (strain K12 HIGH) [<xref rid="B97" ref-type="bibr">97</xref>]. The results of the codon optimization were assessed using the GenScript [<xref rid="B98" ref-type="bibr">98</xref>] Rare Codon Analysis Tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.genscript.com/tools/rare-codon-analysis/" ext-link-type="uri">https://www.genscript.com/tools/rare-codon-analysis/</ext-link>). The in silico cloning of the vaccine construct was performed using SnapGene software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.snapgene.com" ext-link-type="uri">https://www.snapgene.com</ext-link>). The pET-28a (+) expression vector, obtained from the Addgene database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.addgene.org/" ext-link-type="uri">https://www.addgene.org/</ext-link>) [<xref rid="B99" ref-type="bibr">99</xref>], was selected as the cloning vector. The codon-optimized vaccine construct sequence was modified to include the Shine&#8211;Dalgarno sequence, a stop codon, and restriction sites for EcoRI and BamHI enzymes at the 5&#8242; and 3&#8242; ends, respectively. After cloning, the vector was subjected to a 1% agarose gel electrophoresis simulation. In the simulation, the lanes were loaded with a molecular weight ladder, the vaccine construct, the pET-28a (+) vector, and the result of the cloning process.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>In this study, we employed a reverse vaccinology approach to select vaccine candidates from extracellular, periplasmic, and OMPs of <italic toggle="yes">B. canis</italic>. Immunodominant B- and T-cell epitopes were identified within these proteins, and they were assembled using appropriate amino acid connectors (linkers) and molecular adjuvants to create a novel multiepitope vaccine.</p><sec id="sec3.1"><title>3.1. Selection of Vaccine Candidates</title><p>The genome of <italic toggle="yes">B. canis</italic>, obtained from the GCF_000740335.1 database, revealed a total of 2779 proteins identified directly from the genomic data. Analysis using the PSORTb server indicates that 1309 proteins are cytoplasmic, 640 are associated with the cytoplasmic membrane, 14 are extracellular, 31 are OMPs, 82 are periplasmic proteins, and 703 proteins have an undefined cellular location (<xref rid="fig2" ref-type="fig">Figure 2</xref>). Proteins classified as cytoplasmic or with undefined cellular localization were excluded for further analyses. Subsequent alignment with the VFDB for the <italic toggle="yes">Brucella</italic> genus using BLASTp revealed that 84 of the 753 extracellular, cytoplasmic membrane and OMPs are known virulence factors. Next, 57 essential proteins were identified by comparing them with the database comprising the essential genes (DEG). To eliminate homologous proteins found in dogs and mice, a BLASTp search against the proteome of these species was conducted, narrowing the candidates to 20 proteins. Finally, out of the 20 selected proteins, only four were chosen as vaccine candidates for possessing fewer than two transmembrane regions, thus avoiding the selection of epitopes located within these domains. These proteins include three cytoplasmic membrane proteins (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004684587.1">WP_004684587.1</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004690079.1">WP_004690079.1</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004692008.1">WP_004692008.1</ext-link>) and one OMP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_006133077.1">WP_006133077.1</ext-link>). The scores obtained from PSORTb, VFDB, and DEG servers for these candidate proteins are detailed in Table <xref rid="supplementary-material-1" ref-type="sec">S3</xref>. According to VaxiJen, each candidate exhibited an antigenic potential score ranging from 0.4321 to 0.7680. Additionally, scores from ANTIGENpro ranged from 0.099321 to 0.883782. Furthermore, the molecular weight of these proteins is below 100&#8201;kDa, and only one of them (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004684587.1">WP_004684587.1</ext-link>) contains both a transmembrane region and a signal peptide. Regarding topology, three of these proteins exhibit a globular topology, while the protein <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_006133077.1">WP_006133077.1</ext-link> has a beta topology (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.2"><title>3.2. Prediction of Epitopes for B Cells and T Cells</title><p>Upon selecting the peptides and aligning the 16-mer sequences for B and the 8&#8211;11-mer sequences for T cells with their respective protein sequences, six overlapping epitopes were identified (<xref rid="fig3" ref-type="fig">Figure 3</xref>). These six overlapping epitopes were determined to be nonallergenic and nontoxic; furthermore, three were predicted to induce an INF-gamma response (<xref rid="fig4" ref-type="fig">Figure 4</xref>). When looking at the antigenicity assessment of the overlapping epitopes, some peptides fell into the nonantigen category (<xref rid="fig4" ref-type="fig">Figure 4</xref>), but these were not eliminated due to their high scores observed in the B- and T-cell epitope predictions independently (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec3.3"><title>3.3. Design of the Multiepitope Chimeric Vaccine</title><p>The six peptides were connected with flexible GSGS linkers and flanked with the CTB and TpD adjuvant sequences at the N- and C-terminal ends, respectively. The CTB sequence was connected using the rigid EAAAK linker, while the TpD epitope was linked with GSGS (<xref rid="fig5" ref-type="fig">Figure 5</xref>A,B). The AlphaFold server performed the tertiary structure prediction of the vaccine protein (<xref rid="fig5" ref-type="fig">Figure 5</xref>C), which was then refined by GalaxyRefine to derive the 3D structural model. This vaccine construct demonstrated high antigenicity, evidenced by VaxiJen and ANTIGENpro scores of 0.74 and 0.93, respectively. SOLpro analysis indicated a solubility probability of 0.52 for the protein. Additionally, the model is considered nonallergenic and nontoxic (<xref rid="tab2" ref-type="table">Table 2</xref>). Physicochemically, the construct has an optimal molecular weight of 30.3&#8201;kDa for recombinant production in bacterial expression systems. It has a GRAVY index of &#8722;0.117, reflecting its hydrophilic nature. The theoretical isoelectric point (pI) was determined to be 9.66, with an aliphatic index of 84.15 and an instability index of 30.21 (<xref rid="tab2" ref-type="table">Table 2</xref>). These physicochemical properties suggest the vaccine construct is thermostable across various temperature conditions.</p></sec><sec id="sec3.4"><title>3.4. Prediction of Secondary Structure</title><p>The vaccine construct's secondary structure prediction was composed of 17% <italic toggle="yes">&#223;</italic>-turns, 26.3% <italic toggle="yes">&#945;</italic>-helices, 2.8% 3&#8211;10 helices, and 54% other structures (<xref rid="fig6" ref-type="fig">Figure 6</xref>). The intrinsic disorder analysis revealed that the vaccine construct contains regions with a higher degree of disorder, which may suggest potential interaction sites (Figure <xref rid="supplementary-material-1" ref-type="sec">S1</xref>).</p></sec><sec id="sec3.5"><title>3.5. Prediction, Refinement, and Validation of Tertiary Structure</title><p>The AlphaFold server performed the tertiary structure prediction of the vaccine protein (<xref rid="fig5" ref-type="fig">Figure 5</xref>C), which was then refined by GalaxyRefine to derive the 3D structural model. The stereochemical quality of the model was assessed with a Ramachandran plot, revealing that 97.2% of amino acid residues are in the most favored regions and 2.8% in allowed regions (thus, 100% are within the favored regions) (<xref rid="fig7" ref-type="fig">Figure 7</xref>A). The overall quality factor from ERRAT for the 3D model is 98.0198. The confidence score (<italic toggle="yes">Z</italic> score) for the 3D model is &#8722;4.95 according to ProSA web (<xref rid="fig7" ref-type="fig">Figure 7</xref>B). These validations suggest that the vaccine construct's tertiary structure is accurate compared to experimentally predicted proteins.</p></sec><sec id="sec3.6"><title>3.6. Prediction of Discontinuous B-Cell Epitopes</title><p>A total of 11 discontinuous B-cell epitopes were predicted for the vaccine construct. These epitopes had scores between 0.507 and 0.935. In total, 141 amino acids were identified within these 11 epitopes, with sizes ranging from 4 to 35 amino acids (<xref rid="tab3" ref-type="table">Table 3</xref>). These predictions suggest that the vaccine construct could contain several discontinuous epitopes.</p></sec><sec id="sec3.7"><title>3.7. Structural and Functional Characterization of the Vaccine Construct</title><p>The Disulfide by Design 2 server predicted 18 residue pairs of vaccine construct capable of forming disulfide bonds (Table <xref rid="supplementary-material-1" ref-type="sec">S4</xref>). However, none of these pairs met the energy threshold of less than 2.2 kcal/mol or the <italic toggle="yes">&#967;</italic><sup>3</sup> angle between &#8211;87&#176; and +97&#176;. The signal peptide predicted using SignalP indicated that the vaccine construct was classified as &#8220;other,&#8221; meaning it does not possess a signal peptide (Figure <xref rid="supplementary-material-1" ref-type="sec">S2</xref>). The transmembrane topology prediction was performed using DeepTMHMM, which classified the structure as globular (Figure <xref rid="supplementary-material-1" ref-type="sec">S3</xref>).</p></sec><sec id="sec3.8"><title>3.8. Vaccine-TLR4 Docking Analysis</title><p>Molecular docking studies have revealed that the interaction between the vaccine construct and the <italic toggle="yes">M. musculus</italic> TLR4/MD-2/lipid IVa complex is characterized by a binding energy of &#8722;16.3&#8201;kcal/mol, as calculated by the ClusPro web server (<xref rid="fig8" ref-type="fig">Figure 8</xref>A). This low binding energy suggests a strong affinity between the chimeric vaccine construct and the TLR4 receptor complex. The interface between the multiepitope vaccine (chain B) and TLR4 receptor (chain A) is defined by six hydrogen bonds and 61 nonbonding interactions. Additionally, when involving the multiepitope vaccine (chain B) and MD-2 of the TLR4/MD-2/lipid IVa complex (chain C), there is one salt bridge, six hydrogen bonds, and 86 nonbonding interactions, as shown in <xref rid="fig8" ref-type="fig">Figure 8</xref>B. Furthermore, PDBsum provided a graphical representation of the interacting residues between the multiepitope vaccine construct and TLR4 (<xref rid="fig8" ref-type="fig">Figure 8</xref>C) and a graphical representation of the interaction between the multiepitope vaccine and MD-2 (<xref rid="fig8" ref-type="fig">Figure 8</xref>D). These results suggest that the vaccine construct could interact with the TLR4/MD-2/lipid IVa complex of <italic toggle="yes">M. musculus</italic>. However, the same analysis was conducted with the human TLR4 complex, which yielded equally positive results, as depicted in (Figure <xref rid="supplementary-material-1" ref-type="sec">S4</xref>).</p></sec><sec id="sec3.9"><title>3.9. Molecular Dynamics</title><p>The RMSD of atomic positions of the vaccine construct and the vaccine-TLR4 complex were analyzed based on the backbone atoms of the protein to measure the dynamic behavior and conformational stability from its initial to its final state. The average RMSD values were maintained at less than 2&#8201;nm throughout a 500&#8201;ns simulation, indicating stability after 10&#8201;ns for the free form and 25&#8201;ns when complexed with TLR4 (<xref rid="fig9" ref-type="fig">Figure 9</xref>A,D). This suggests the formation of a stable complex with minimal fluctuations. The Rgyr analysis also supports the development of a compact and stable structure of the vaccine construct and the complex (<xref rid="fig9" ref-type="fig">Figure 9</xref>). Additionally, a study of residual flexibility using RMSF for the C<italic toggle="yes">&#945;</italic> atoms indicated reduced flexibility at the receptor-binding interface (<xref rid="fig9" ref-type="fig">Figure 9</xref>). Collectively, these results confirm that the construct, when associated with TLR4, achieves significant dynamic stability within the 500&#8201;ns of simulation timeframe.</p></sec><sec id="sec3.10"><title>3.10. Normal Mode Analysis</title><p>A normal mode analysis, facilitated by the WEBnma3 API program, was performed to determine the molecular stability and functional motions of the vaccine&#8211;TLR4 complex. A low eigenvalue of 8.5&#8201;&#215;&#8201;10<sup>&#8722;3</sup> indicated a high level of stability in the complex (<xref rid="fig10" ref-type="fig">Figure 10</xref>A). The deformation energies, which reflect the energy associated with each mode, were inversely related to the motion amplitude of that mode (<xref rid="fig10" ref-type="fig">Figure 10</xref>B). Molecular and atomic motions during the protein&#8211;protein interactions were examined using a covariance map that depicted correlations between each pair of residues in the vaccine&#8211;TLR complex (<xref rid="fig10" ref-type="fig">Figure 10</xref>C). Movements within different residue pairs were categorized as correlated (red), uncorrelated (white), and anticorrelated (blue). Fluctuations in atomic positions (<xref rid="fig10" ref-type="fig">Figure 10</xref>D) and atomic displacements (<xref rid="fig10" ref-type="fig">Figure 10</xref>E) of the six modes with the lowest frequencies were also identified. Deformability and fluctuations resulting from the simulation suggested that the vaccine-TLR4 complex maintains a balance of structural flexibility and stability.</p></sec><sec id="sec3.11"><title>3.11. Binding-Free Energy Calculation</title><p>The binding-free energy of the vaccine&#8211;TLR4 complex was determined using the MM-PBSA and MM-GBSA approaches. The total binding-free energy of the complex was calculated to be &#8722;275.87&#8201;kcal/mol using MM-PBSA. The gas energy phase had a negative value for the complex, whereas the solvation energy had positive values. Additionally, each component's energy contribution is detailed in <xref rid="tab4" ref-type="table">Table 4</xref>.</p></sec><sec id="sec3.12"><title>3.12. Codon Optimization and In Silico Cloning of the Vaccine Construct</title><p>The vaccine construct would be 888bp long, with a Codon Adaptation Index (CAI) of 0.86 and a GC content of 0,54%. Using SnapGene software version 7.2.1, the optimized construct was cloned into the pET-28a (+) expression vector between <italic toggle="yes">EcoRI</italic> (192) and <italic toggle="yes">BamHI</italic> (198). The total length of the pET-28a (+) with the inserted construct sequence was found to be 6245bp (<xref rid="fig11" ref-type="fig">Figure 11</xref>A). Additionally, the size of the cloning product was confirmed using the simulated agarose gel electrophoresis tool from SnapGene (<xref rid="fig11" ref-type="fig">Figure 11</xref>B).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>
<italic toggle="yes">Brucella</italic> spp. are Gram-negative, intracellular pathogens causing brucellosis [<xref rid="B100" ref-type="bibr">100</xref>]. Among them, <italic toggle="yes">B. canis</italic>, one of the most prevalent species, is responsible for causing canine brucellosis. This condition is reported globally as a significant public health concern due to the intimate contact between dogs and humans [<xref rid="B101" ref-type="bibr">101</xref>]. Canine brucellosis is characterized by symptoms such as abortion, reproductive failure, and enlarged lymph nodes, and it may occasionally affect the osteoarticular system in dogs. In contrast, in humans, the disease manifests as a febrile syndrome, commonly known as Malta fever, with nonspecific symptoms such as splenomegaly, fatigue, and weakness [<xref rid="B13" ref-type="bibr">13</xref>]. There is currently no prophylactic for either canine or human brucellosis. Although some experimental vaccines for dogs have shown promise in terms of immunogenicity and protection, they rely on attenuated strains that could potentially be pathogenic and exacerbate transmission among canines and humans [<xref rid="B102" ref-type="bibr">102</xref>]. Innovative proteomic and bioinformatic methods enable the identification of virulence factors that play a role in the infectious process of these pathogens, offering potential targets for vaccine development [<xref rid="B102" ref-type="bibr">102</xref>]. The study of <italic toggle="yes">B. canis</italic> proteome is crucial as it provides an extensive protein analysis across various biochemical and pathological pathways, aiding the identification of novel drug targets. In this study, we employed reverse vaccinology approaches and subtractive genomics-based computational schemes to examine the complete proteome of <italic toggle="yes">B. canis</italic> strain RM6/66 for the construction of a new multiepitope vaccine candidate to evaluate its potential efficacy, including its physicochemical properties, safety, and immunogenicity.</p><p>The vaccine model was designed by overlapping MHC-I, MHC-II, and B-cell epitopes for mouse H2 alleles, integrated with specific connectors and adjuvant sequences for a chimeric vaccine as predicted by specialized and validated bioinformatic tool (Table <xref rid="supplementary-material-1" ref-type="sec">S1</xref>). Overlapping epitopes were selected because their use makes it possible to induce both humoral and cellular immune responses [<xref rid="B103" ref-type="bibr">103</xref>], achieves higher population coverage [<xref rid="B104" ref-type="bibr">104</xref>], and results in a more compact construct [<xref rid="B105" ref-type="bibr">105</xref>&#8211;<xref rid="B107" ref-type="bibr">107</xref>] compared to the use of concatenated epitopes. These vaccine constructs are advantageous because they can contain more epitopes than those constructed with concatenated peptides [<xref rid="B108" ref-type="bibr">108</xref>], and these epitopes are conserved while avoiding repetition in the same sequence [<xref rid="B107" ref-type="bibr">107</xref>]. To prevent the loss of immunodominant epitopes, a threshold for the IC50 value was set during epitope prediction [<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>]. MHC-I and MHC-II epitopes are crucial as they enable cytotoxic T cells to identify and eliminate infected cells, thus conferring broader immunity [<xref rid="B110" ref-type="bibr">110</xref>]. Meanwhile, humoral immune responses mediated by B cells involve antibody secretion to neutralize reactive pathogens and establish long-term immunological memory against future exposures [<xref rid="B111" ref-type="bibr">111</xref>]. T cells, both cytotoxic and helpers, activate cellular immune responses essential for halting the spread of disease, either by targeting infected cells for elimination or by secreting antimicrobial cytokines that contribute to sustained immunity for years or even decades [<xref rid="B112" ref-type="bibr">112</xref>]. Since the candidate must first be evaluated in a murine model, we used the mouse H-2 allele for epitope prediction. Mice remain a premier animal model for MHC research because their alleles are fully sequenced, well-characterized [<xref rid="B113" ref-type="bibr">113</xref>], and integrated into bioinformatic tools such as NetMHCpan. Although the dog leukocyte antigen (DLA) genomic regions are also completely sequenced with some alleles available for epitope prediction [<xref rid="B114" ref-type="bibr">114</xref>], detailed information regarding genomic differences among alleles remains limited [<xref rid="B115" ref-type="bibr">115</xref>]. Recent studies have analyzed the diversity of haplotypes [<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B116" ref-type="bibr">116</xref>] and determined their association with diseases such as chronic enteropathy [<xref rid="B117" ref-type="bibr">117</xref>] and meningoencephalomyelitis [<xref rid="B118" ref-type="bibr">118</xref>]. As a result, one class I DLA allele is now available in NetMHCpan. Thus, the low knowledge of class I and II alleles restricts the prediction of epitopes for dogs. Among the six overlapping epitopes, two possess the ability to induce IFN-<italic toggle="yes">&#947;</italic>, indicating that IFN-<italic toggle="yes">&#947;</italic> enhances pathogen clearance when produced at elevated levels following vaccination [<xref rid="B110" ref-type="bibr">110</xref>, <xref rid="B119" ref-type="bibr">119</xref>]. Furthermore, linkers are strategically incorporated to ensure that each epitope can trigger an independent immune response and to avoid the formation of novel epitopes that might disrupt the immune activity induced by the original epitope. Linkers also serve to enhance the stability and expression of the vaccine [<xref rid="B120" ref-type="bibr">120</xref>]. The EAAAK linker contributes rigidity, which supports the helical conformation of the construct, providing stability and functionality [<xref rid="B66" ref-type="bibr">66</xref>]. Conversely, the GSGSG linker offers flexibility due to the small size of its constituent amino acids, which promotes interaction between the protein domains [<xref rid="B121" ref-type="bibr">121</xref>]. Furthermore, adjuvants play a pivotal role in the vaccine formulation by enhancing the antigen-specific immune response, preserving peptide stability, and improving immunogenicity [<xref rid="B122" ref-type="bibr">122</xref>]. The CTB adjuvant, a nontoxic component of the CTB subunit, has an affinity for monosialotetrahexosylganglioside (GM1), a glycosphingolipid present in antigen-presenting cells such as macrophages, dendritic cells, and B cells. This ensures optimal engagement with the immune system. CTB is commonly employed to bind antigens, achieved either through genetic fusion or chemical conjugation, resulting in markedly augmented immune responses to the antigens [<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>]. Conversely, TpD, an epitope known as a potent universal adjuvant to the CD4 T-cell helper, has been shown to efficiently activate human PBMCs in vitro and enhance immune responses in vivo in mice and nonhuman primates [<xref rid="B123" ref-type="bibr">123</xref>].</p><p>The inclusion of 3D structural data is critical for understanding biomolecular interactions between the proposed vaccine and the murine immune receptors. Tertiary structural prediction and validation of the vaccine's candidates were conducted using an array of computational tools. The vaccine construct showed promising attributes of quality and stability, as indicated by Ramachandran plot assessments and <italic toggle="yes">Z</italic>-score evaluations. Molecular docking assessed the binding affinity of the vaccine construct with the murine TLR4/MD2 complex, which was used instead of TLR4 only because MD2 is critical for stabilizing ligand binding to the TLR4 receptor, providing a more accurate representation of the physiological context for immune activation [<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>]. The analysis revealed robust interactions with MD2 and significant vaccine-TLR4 binding, likely facilitated by hydrogen bonding and salt bridge formation that are conducive to a favorable immune response. Several studies support vaccine engagement with the TLR4/MD2 complex, which elicits a strong T-cell response and increases IFN-<italic toggle="yes">&#947;</italic> production [<xref rid="B126" ref-type="bibr">126</xref>&#8211;<xref rid="B128" ref-type="bibr">128</xref>]. Molecular dynamics and normal mode analyses were performed to investigate the vaccine-TLR4 complex's stability and dynamic behavior. Simulation results confirmed consistent binding stability, as indicated by RMSD, Rgyr, and RMSF metrics, underscoring the importance of stability for long-term immunity [<xref rid="B129" ref-type="bibr">129</xref>]. A normal mode analysis provided insights into eigenvalues, strain energy, displacements, fluctuations, and correlations between pairs of residues, demonstrating the vaccine construct's flexibility and stability in its interaction with TLR4/MD2 [<xref rid="B130" ref-type="bibr">130</xref>].</p><p>To date, the design of a multiepitope vaccine targeting <italic toggle="yes">B. canis</italic> has not been reported; however, similar efforts have been proposed against <italic toggle="yes">B. melitensis</italic> [<xref rid="B131" ref-type="bibr">131</xref>&#8211;<xref rid="B133" ref-type="bibr">133</xref>], <italic toggle="yes">B. abortus</italic> [<xref rid="B35" ref-type="bibr">35</xref>], and other <italic toggle="yes">Brucella</italic> species [<xref rid="B134" ref-type="bibr">134</xref>&#8211;<xref rid="B137" ref-type="bibr">137</xref>]. These studies employed molecular dynamics to validate the stability and subsequent immunogenicity of their vaccine constructs. In this context, the proposal to develop a multiepitope vaccine for <italic toggle="yes">B. canis</italic> is well-supported by bioinformatic research, as previously demonstrated for pathogens such as HCV, <italic toggle="yes">P. penneri</italic>, and <italic toggle="yes">L. henipavirus</italic> [<xref rid="B138" ref-type="bibr">138</xref>&#8211;<xref rid="B140" ref-type="bibr">140</xref>]. Considering the physicochemical properties and predicted immunogenic values, it can be inferred that this multiepitope chimeric vaccine is stable and shows promising results, indicating that it is likely to maintain its immunogenicity and stability during the purification and preparation stages. Furthermore, the predictions suggest that the vaccine is highly antigenic with minimal allergenicity and toxicity, making it a safe and robust candidate for inducing a strong immune response upon immunization. Interestingly, due to the monophyletic characteristics of the <italic toggle="yes">Brucella</italic> group, the immunogenicity induced by this candidate vaccine may provide cross-reactivity against several <italic toggle="yes">Brucella</italic> species, particularly <italic toggle="yes">B. canis</italic> strains (data not shown). However, these in silico results&#8212;based on H2 alleles for epitope prediction, which are fully sequenced and well-characterized&#8212;raise several questions. These include whether the predicted immunogenicity can be replicated in murine models and what adjustments would be required to transfer the vaccine's design from H2 alleles to canine leukocyte antigen (DLA) alleles, should it prove to be immunogenic.</p><p>In addition to the aforementioned characteristics, in silico immune simulation suggests that this vaccine can effectively stimulate both humoral and cellular immune responses (Figure <xref rid="supplementary-material-1" ref-type="sec">S5</xref>). However, the limitations of this bioinformatic approach must be acknowledged, as reliance on in silico predictions may not fully capture the complexities of immune responses in living organisms. Genetic variability among individuals and potential differences in epitope presentation between species may also influence the vaccine's efficacy [<xref rid="B141" ref-type="bibr">141</xref>]. The next steps will involve conducting in vitro and in vivo tests to validate these findings and compare them with experimental data.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>This study introduces a novel vaccine construct candidate with predicted immunogenicity against <italic toggle="yes">B. canis</italic>, designed to elicit a substantial immune response in the immunized host. Developing a vaccine to prevent canine brucellosis is essential, as it not only addresses the health of the canine population but also mitigates the risk of zoonotic transmission associated with this disease. These preliminary findings lay the groundwork for further validation through the expression and purification of the recombinant protein and its evaluation in in vivo experimental assays.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by FONDECYT grant 1230018 awarded to AO and Faculty of Biological Sciences, Universidad de Concepci&#243;n.</p></ack><sec sec-type="data-availability"><title>Data Availability Statement</title><p>Raw data will be available upon request to the corresponding author. Additional materials are available in the Supporting Information Files.</p></sec><sec><title>Ethics Statement</title><p>This article contains no studies with human participants or animals performed.</p></sec><sec><title>Disclosure</title><p>The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="Funding"><title>Funding</title><p>This research was supported by the Fondo Nacional de Desarrollo Cient&#237;fico y Tecnol&#243;gico (Fondecyt 1230018) and Facultad de Ciencias Biologicas, Universidad de Concepci&#243;n, Chile.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supporting Information</title><p>Additional supporting information can be found online in the Supporting Information section.</p><supplementary-material id="supp-1" position="float" content-type="local-data" orientation="portrait"><label>Supporting Information</label><caption><p>Table S1. The servers and databases used in the design of the multiepitope vaccine. Table S2. Cutoff values of the servers used in the design of the multiepitope vaccine. Table S3. Scores of the candidate's proteins in PSORTb, VFDB, and DEG. Table S4. List of vaccine residue pairs with the potential to form disulfide bonds, along with their <italic toggle="yes">&#967;</italic><sup>3</sup> angles and energy values. Figure S1. Intrinsic disorder of the vaccine construct predicted by IUPred3. The intrinsic disorder is evaluated based on the position of amino acids versus their score. Figure S2. Signal peptide prediction of the vaccine construct predicted by SignalP 6.0 server. Figure S3. Transmembrane topology prediction for the vaccine construct by DeepTMHMM server. Figure S4. Representation of the molecular docking complex between chimeric multiepitope vaccine and TLR4 complex. (A) Three-dimensional visualization of the docking complex of the vaccine construct (in red) with human TLR4/MD-2/lipid IVa complex (in purpura). (B) Molecular interactions between chain A of the TLR4 receptor molecule and chain B of the vaccine construct, and (C) interactions between chain B and chain C of the TLR4/MD-2/lipid IVa complex. (D) Hydrogen-bond interactions between chain B and chain C. Figure S5. Immune simulation with vaccine construct after two doses of vaccine. (A) Antigen and immunoglobulins after two doses. (B) B lymphocytes response. (C) CD4 T-helper lymphocytes count and (D) subdivided per entity-state (active, resting, anergic, and duplicating). (E) CD8 T-cytotoxic lymphocytes count and (F) subdivided per entity-state. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kraken.iac.rm.cnr.it/C-IMMSIM/" ext-link-type="uri">https://kraken.iac.rm.cnr.it/C-IMMSIM/</ext-link>).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="6348238.f1.docx" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halling</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Peterson-Burch</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Bricker</surname><given-names>B. J.</given-names></name><etal/></person-group><article-title>Completion of the Genome Sequence of <italic toggle="yes">Brucella abortus</italic> and Comparison to the Highly Similar Genomes of <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella suis</italic></article-title><source><italic toggle="yes">Journal of Bacteriology</italic></source><year>2005</year><volume>187</volume><issue>8</issue><fpage>2715</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1128/JB.187.8.2715-2726.2005</pub-id><pub-id pub-id-type="other">2-s2.0-16844363464</pub-id><pub-id pub-id-type="pmid">15805518</pub-id><pub-id pub-id-type="pmcid">PMC1070361</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Figueiredo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ficht</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>L. G.</given-names></name></person-group><article-title>Pathogenesis and Immunobiology of Brucellosis: Review of Brucella-Host Interactions</article-title><source><italic toggle="yes">The American Journal of Pathology</italic></source><year>2015</year><volume>185</volume><issue>6</issue><fpage>1505</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-84929878253</pub-id><pub-id pub-id-type="pmid">25892682</pub-id><pub-id pub-id-type="pmcid">PMC4450313</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atluri</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Den Hartigh</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Tsolis</surname><given-names>R. M.</given-names></name></person-group><article-title>Interactions of the Human Pathogenic Brucella Species With Their Hosts</article-title><source><italic toggle="yes">Annual Review of Microbiology</italic></source><year>2011</year><volume>65</volume><issue>1</issue><fpage>523</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-090110-102905</pub-id><pub-id pub-id-type="other">2-s2.0-80053275984</pub-id><pub-id pub-id-type="pmid">21939378</pub-id></element-citation></ref><ref id="B4" content-type="misc"><label>4</label><element-citation publication-type="other"><collab>World Organization for Animal Health (WOAH)</collab><article-title>Terrestrial Manual Online Access</article-title><year>2024</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-manual-online-access" ext-link-type="uri">https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-manual-online-access</ext-link></comment></element-citation></ref><ref id="B5" content-type="misc"><label>5</label><element-citation publication-type="other"><collab>World Organization for Animal Health (WOAH)</collab><article-title>The Control of Neglected Zoonotic Diseases: A Route to Poverty Alleviation</article-title><year>2006</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications-detail-redirect/9789241594301" ext-link-type="uri">https://www.who.int/publications-detail-redirect/9789241594301</ext-link></comment></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfroid</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cloeckaert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liautard</surname><given-names>J. P.</given-names></name><etal/></person-group><article-title>From the Discovery of the Malta Fever&#8217;s Agent to the Discovery of a Marine Mammal Reservoir, Brucellosis has Continuously Been a Re-Emerging Zoonosis</article-title><source><italic toggle="yes">Veterinary Research</italic></source><year>2005</year><volume>36</volume><issue>3</issue><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1051/vetres:2005003</pub-id><pub-id pub-id-type="other">2-s2.0-19144367380</pub-id><pub-id pub-id-type="pmid">15845228</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seleem</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N.</given-names></name></person-group><article-title>Brucellosis: A Re-Emerging Zoonosis</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2010</year><volume>140</volume><issue>3-4</issue><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2009.06.021</pub-id><pub-id pub-id-type="other">2-s2.0-74249111903</pub-id><pub-id pub-id-type="pmid">19604656</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Papadimitriou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Akritidis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Christou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsianos</surname><given-names>E. V.</given-names></name></person-group><article-title>The New Global Map of Human Brucellosis</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2006</year><volume>6</volume><issue>2</issue><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70382-6</pub-id><pub-id pub-id-type="other">2-s2.0-31344450203</pub-id><pub-id pub-id-type="pmid">16439329</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Crump</surname><given-names>L.</given-names></name><name name-style="western"><surname>Greter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hattendorf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schelling</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zinsstag</surname><given-names>J.</given-names></name></person-group><article-title>Clinical Manifestations of Human Brucellosis: A Systematic Review and Meta-Analysis</article-title><source><italic toggle="yes">PLoS neglected tropical diseases</italic></source><volume>6</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0001929</pub-id><pub-id pub-id-type="other">2-s2.0-84872015632</pub-id><pub-id pub-id-type="publisher-id">e1929</pub-id><pub-id pub-id-type="pmcid">PMC3516581</pub-id><pub-id pub-id-type="pmid">23236528</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Research Progress on Complications of Brucellosis</article-title><source><italic toggle="yes">Frontiers in Cellular and Infection Microbiology</italic></source><year>2023</year><volume>13</volume><pub-id pub-id-type="doi">10.3389/fcimb.2023.1136674</pub-id><pub-id pub-id-type="publisher-id">1136674</pub-id><pub-id pub-id-type="pmcid">PMC10102637</pub-id><pub-id pub-id-type="pmid">37065189</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanke</surname><given-names>M. M.</given-names></name></person-group><article-title>Canine Brucellosis</article-title><source><italic toggle="yes">Animal Reproduction Science</italic></source><year>2004</year><volume>82-83</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.anireprosci.2004.05.005</pub-id><pub-id pub-id-type="other">2-s2.0-3543090486</pub-id><pub-id pub-id-type="pmid">15271453</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djokic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Freddi</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Massis</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The Emergence of <italic toggle="yes">Brucella canis</italic> as a Public Health Threat in Europe: What We Know and What We Need to Learn</article-title><source><italic toggle="yes">Emerging Microbes &amp; Infections</italic></source><year>2023</year><volume>12</volume><issue>2</issue><pub-id pub-id-type="doi">10.1080/22221751.2023.2249126</pub-id><pub-id pub-id-type="publisher-id">2249126</pub-id><pub-id pub-id-type="pmcid">PMC10540651</pub-id><pub-id pub-id-type="pmid">37649455</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Mol</surname><given-names>J. P. S.</given-names></name><name name-style="western"><surname>Eckstein</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pa&#237;x&#227;o</surname><given-names>T. A.</given-names></name></person-group><article-title>Canine Brucellosis: An Update</article-title><source><italic toggle="yes">Frontiers in Veterinary Science</italic></source><year>2021</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fvets.2021.594291</pub-id><pub-id pub-id-type="publisher-id">594291</pub-id><pub-id pub-id-type="pmcid">PMC7962550</pub-id><pub-id pub-id-type="pmid">33738302</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollett</surname><given-names>R. B.</given-names></name></person-group><article-title>Canine Brucellosis: Outbreaks and Compliance</article-title><source><italic toggle="yes">Theriogenology</italic></source><year>2006</year><volume>66</volume><issue>3</issue><fpage>575</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.theriogenology.2006.04.011</pub-id><pub-id pub-id-type="other">2-s2.0-33745842269</pub-id><pub-id pub-id-type="pmid">16716382</pub-id></element-citation></ref><ref id="B15" content-type="book"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Carmichael</surname><given-names>L. G. C.</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Greene</surname><given-names>C.</given-names></name></person-group><source><italic toggle="yes">Brucelosis Canina en Enfermedades Infecciosas en Perros y Gatos</italic></source><year>2008</year><edition>3a</edition><publisher-loc>Buenos Aires, Argentina</publisher-loc><fpage>411</fpage><lpage>424</lpage></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Souza</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Mol</surname><given-names>J. P. D. S.</given-names></name><etal/></person-group><article-title>Tissue Distribution and Cell Tropism of <italic toggle="yes">Brucella canis</italic> in Naturally Infected Canine Foetuses and Neonates</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2018</year><volume>8</volume><issue>8</issue><pub-id pub-id-type="doi">10.1038/s41598-018-25651-x</pub-id><pub-id pub-id-type="other">2-s2.0-85046861159</pub-id><pub-id pub-id-type="publisher-id">7203</pub-id><pub-id pub-id-type="pmcid">PMC5940860</pub-id><pub-id pub-id-type="pmid">29740101</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyuranecz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szeredi</surname><given-names>L.</given-names></name><name name-style="western"><surname>R&#243;nai</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Detection of Brucella Canis-Induced Reproductive Diseases in a Kennel</article-title><source><italic toggle="yes">Journal of Veterinary Diagnostic Investigation</italic></source><year>2011</year><volume>23</volume><issue>1</issue><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1177/104063871102300127</pub-id><pub-id pub-id-type="other">2-s2.0-78751489164</pub-id><pub-id pub-id-type="pmid">21217047</pub-id></element-citation></ref><ref id="B18" content-type="misc"><label>18</label><element-citation publication-type="other"><collab>The Center for Food Security and Public Health</collab><article-title>Brucelosis Canina: <italic toggle="yes">Brucella canis</italic></article-title><year>2009</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cfsph.iastate.edu/Factsheets/es/brucellosis_canis-es.pdf" ext-link-type="uri">https://www.cfsph.iastate.edu/Factsheets/es/brucellosis_canis-es.pdf</ext-link></comment></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>E. J.</given-names></name></person-group><article-title>An Overview of Human Brucellosis</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>1995</year><volume>21</volume><issue>2</issue><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1093/clinids/21.2.283</pub-id><pub-id pub-id-type="other">2-s2.0-0029153199</pub-id><pub-id pub-id-type="pmid">8562733</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akritidis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bosilkovski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsianos</surname><given-names>E.</given-names></name></person-group><article-title>Brucellosis</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>22</issue><fpage>2325</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.1056/NEJMra050570</pub-id><pub-id pub-id-type="other">2-s2.0-19644363222</pub-id><pub-id pub-id-type="pmid">15930423</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauffman</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>C. A.</given-names></name></person-group><article-title>Canine Brucellosis</article-title><source><italic toggle="yes">Veterinary Clinics of North America: Small Animal Practice</italic></source><year>2019</year><volume>49</volume><fpage>763</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2019.02.013</pub-id><pub-id pub-id-type="other">2-s2.0-85063759380</pub-id><pub-id pub-id-type="pmid">30961996</pub-id></element-citation></ref><ref id="B22" content-type="misc"><label>22</label><element-citation publication-type="other"><collab>GOVUK</collab><article-title>Zoonoses and Veterinary Public Health: Disease Surveillance Reports</article-title><year>2023</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gov.uk/government/publications/zoonoses-and-veterinary-public-health-disease-surveillance-reports" ext-link-type="uri">https://www.gov.uk/government/publications/zoonoses-and-veterinary-public-health-disease-surveillance-reports</ext-link></comment></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinn-Woodcock</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frye</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A One-Health Review on Brucellosis in the United States</article-title><source><italic toggle="yes">Journal of the American Veterinary Medical Association</italic></source><year>2023</year><volume>261</volume><issue>4</issue><fpage>451</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.2460/javma.23.01.0033</pub-id><pub-id pub-id-type="pmid">36862545</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchinson</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R. P.</given-names></name></person-group><article-title>Seropositivity to Toxoplasma Infection in Sheep Samples Submitted to Animal and Plant Health Agency Laboratories Between 2005 and 2012</article-title><source><italic toggle="yes">Veterinary Record</italic></source><year>2015</year><volume>176</volume><issue>22</issue><fpage>573</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1136/vr.102114</pub-id><pub-id pub-id-type="other">2-s2.0-84930318545</pub-id><pub-id pub-id-type="pmid">25888604</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hensel</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Negron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A. M.</given-names></name></person-group><article-title>Brucellosis in Dogs and Public Health Risk</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2018</year><volume>24</volume><issue>8</issue><fpage>1401</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.3201/eid2408.171171</pub-id><pub-id pub-id-type="other">2-s2.0-85050410918</pub-id><pub-id pub-id-type="pmid">30014831</pub-id><pub-id pub-id-type="pmcid">PMC6056133</pub-id></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebzda</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>L. K.</given-names></name></person-group><article-title>Update on <italic toggle="yes">Brucella canis</italic>: Understanding the Past and Preparing for the Future</article-title><source><italic toggle="yes">Veterinary Clinics of North America&#8211;Small Animal Practice</italic></source><year>2023</year><volume>53</volume><fpage>1047</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2023.05.002</pub-id><pub-id pub-id-type="pmid">37385876</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Sathiyaseelan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parent</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>C. L.</given-names></name></person-group><article-title>Interferon-<italic toggle="yes">&#947;</italic> is Crucial for Surviving a <italic toggle="yes">Brucella abortus</italic> Infection in Both Resistant C57BL/6 and Susceptible BALB/c Mice</article-title><source><italic toggle="yes">Immunology</italic></source><year>2001</year><volume>103</volume><issue>4</issue><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01258.x</pub-id><pub-id pub-id-type="other">2-s2.0-0034886064</pub-id><pub-id pub-id-type="pmid">11529943</pub-id><pub-id pub-id-type="pmcid">PMC1783270</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skendros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boura</surname><given-names>P.</given-names></name></person-group><article-title>Immunity to Brucellosis</article-title><source><italic toggle="yes">Revue Scientifique et Technique de l&#8217;OIE</italic></source><year>2013</year><volume>32</volume><issue>1</issue><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.20506/rst.32.1.2190</pub-id><pub-id pub-id-type="other">2-s2.0-84879453669</pub-id><pub-id pub-id-type="pmid">23837372</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>J. P. A.</given-names></name><name name-style="western"><surname>Paix&#227;o</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R. L.</given-names></name></person-group><article-title>Meta-Analysis and Advancement of Brucellosis Vaccinology</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2016</year><volume>11</volume><issue>11</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0166582</pub-id><pub-id pub-id-type="other">2-s2.0-84995561915</pub-id><pub-id pub-id-type="publisher-id">e0166582</pub-id><pub-id pub-id-type="pmcid">PMC5112997</pub-id><pub-id pub-id-type="pmid">27846274</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palomares-Resendiz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Arellano-Reynoso</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Castro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Immunogenic Response of <italic toggle="yes">Brucella canis</italic> virB10 and virB11 Mutants in a Murine Model</article-title><source><italic toggle="yes">Frontiers in Cellular and Infection Microbiology</italic></source><year>2012</year><volume>19</volume><issue>2</issue><pub-id pub-id-type="doi">10.3389/fcimb.2012.00035</pub-id><pub-id pub-id-type="publisher-id">35</pub-id><pub-id pub-id-type="pmcid">PMC3417389</pub-id><pub-id pub-id-type="pmid">22919627</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A Safe and Molecular-Tagged <italic toggle="yes">Brucella canis</italic> Ghosts Confer Protection Against Virulent Challenge in Mice</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2017</year><volume>204</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2017.04.027</pub-id><pub-id pub-id-type="other">2-s2.0-85018459655</pub-id><pub-id pub-id-type="pmid">28532790</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausse</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Ghersi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The Vaccine Candidate BLSOmp31 Protects Mice Against <italic toggle="yes">Brucella canis</italic> Infection</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2013</year><volume>31</volume><issue>51</issue><fpage>6129</fpage><lpage>6135</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.041</pub-id><pub-id pub-id-type="other">2-s2.0-84888434325</pub-id><pub-id pub-id-type="pmid">23906889</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Wanke</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S. M.</given-names></name><etal/></person-group><article-title>Immunization With Brucella VirB Proteins Reduces Organ Colonization in Mice through a Th1-Type Immune Response and Elicits a Similar Immune Response in Dogs</article-title><source><italic toggle="yes">Clinical and Vaccine Immunology</italic></source><year>2015</year><volume>22</volume><issue>3</issue><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1128/CVI.00653-14</pub-id><pub-id pub-id-type="other">2-s2.0-84923923104</pub-id><pub-id pub-id-type="pmid">25540276</pub-id><pub-id pub-id-type="pmcid">PMC4340900</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckstein</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mol</surname><given-names>J. P. S.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F. B.</given-names></name><etal/></person-group><article-title>
<italic toggle="yes">Brucella ovis</italic> Mutant in ABC Transporter Protects Against <italic toggle="yes">Brucella canis</italic> Infection in Mice and it is Safe for Dogs</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2020</year><volume>15</volume><issue>4</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0231893</pub-id><pub-id pub-id-type="publisher-id">e0231893</pub-id><pub-id pub-id-type="pmcid">PMC7162469</pub-id><pub-id pub-id-type="pmid">32298378</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escalona</surname><given-names>E.</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D.</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A.</given-names></name></person-group><article-title>Immunogenicity of a Multi-Epitope DNA Vaccine Encoding Epitopes From Cu&#8211;Zn Superoxide Dismutase and Open Reading Frames of <italic toggle="yes">Brucella abortus</italic> in Mice</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fimmu.2017.00125</pub-id><pub-id pub-id-type="other">2-s2.0-85014337101</pub-id><pub-id pub-id-type="publisher-id">125</pub-id><pub-id pub-id-type="pmcid">PMC5298974</pub-id><pub-id pub-id-type="pmid">28232837</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aiman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A. A.</given-names></name><etal/></person-group><article-title>Vaccinomics-Based Next-Generation Multi-Epitope Chimeric Vaccine Models Prediction Against Leishmania Tropica - A Hierarchical Subtractive Proteomics and Immunoinformatics Approach</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2023</year><volume>14</volume><pub-id pub-id-type="doi">10.3389/fimmu.2023.1259612</pub-id><pub-id pub-id-type="publisher-id">1259612</pub-id><pub-id pub-id-type="pmcid">PMC10540849</pub-id><pub-id pub-id-type="pmid">37781384</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S. R.</given-names></name><etal/></person-group><article-title>Immunoinformatics Approach for Designing a Universal Multiepitope Vaccine Against Chandipura Virus</article-title><source><italic toggle="yes">Microbial Pathogenesis</italic></source><year>2022</year><volume>162</volume><pub-id pub-id-type="doi">10.1016/j.micpath.2021.105358</pub-id><pub-id pub-id-type="publisher-id">105358</pub-id><pub-id pub-id-type="pmid">34902539</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wriggers</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>P. A.</given-names></name></person-group><article-title>Control of Protein Functional Dynamics by Peptide Linkers, Biopolymers - Peptide Science Section</article-title><source><italic toggle="yes">Peptide Science</italic></source><year>2005</year><volume>80</volume><issue>6</issue><fpage>736</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1002/bip.20291</pub-id><pub-id pub-id-type="other">2-s2.0-33144464467</pub-id><pub-id pub-id-type="pmid">15880774</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvizpour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pourseif</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Razmara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rafi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y.</given-names></name></person-group><article-title>Epitope-Based Vaccine Design: A Comprehensive Overview of Bioinformatics Approaches</article-title><source><italic toggle="yes">Drug Discovery Today</italic></source><year>2020</year><volume>25</volume><issue>6</issue><fpage>1034</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.03.006</pub-id><pub-id pub-id-type="pmid">32205198</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R. A.</given-names></name></person-group><article-title>Vaccine Adjuvants: Putting Innate Immunity to Work</article-title><source><italic toggle="yes">Immunity</italic></source><year>2010</year><volume>33</volume><issue>4</issue><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="other">2-s2.0-77958498224</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D. T.</given-names></name></person-group><article-title>Emerging Concepts in the Science of Vaccine Adjuvants</article-title><source><italic toggle="yes">Nature Reviews Drug Discovery</italic></source><year>2021</year><volume>20</volume><issue>6</issue><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J. B.</given-names></name></person-group><article-title>Vaccine Adjuvants: Mode of Action</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2013</year><volume>4</volume><pub-id pub-id-type="doi">10.3389/fimmu.2013.00214</pub-id><pub-id pub-id-type="other">2-s2.0-84883687740</pub-id><pub-id pub-id-type="publisher-id">214</pub-id><pub-id pub-id-type="pmcid">PMC3728558</pub-id><pub-id pub-id-type="pmid">23914187</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>F. T.</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name></person-group><article-title>Vaccine Adjuvants: From 1920 to 2015 and beyond</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2015</year><volume>3</volume><issue>2</issue><fpage>320</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayers</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Cavanaugh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K.</given-names></name><etal/></person-group><article-title>GenBank</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2022</year><volume>50</volume><issue>D1</issue><fpage>D161</fpage><lpage>D164</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1135</pub-id><pub-id pub-id-type="pmid">34850943</pub-id><pub-id pub-id-type="pmcid">PMC8690257</pub-id></element-citation></ref><ref id="B45" content-type="article"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>N. Y.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Laird</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>PSORTb 3.0: Improved Protein Subcellular Localization Prediction With Refined Localization Subcategories and Predictive Capabilities for All Prokaryotes</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2010</year><volume>26</volume><issue>13</issue><fpage>1608</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq249</pub-id><pub-id pub-id-type="other">2-s2.0-77954199597</pub-id><pub-id pub-id-type="pmid">20472543</pub-id><pub-id pub-id-type="pmcid">PMC2887053</pub-id></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>VFDB 2022: A General Classification Scheme for Bacterial Virulence Factors</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2022</year><volume>50</volume><issue>D1</issue><fpage>D912</fpage><lpage>D917</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1107</pub-id><pub-id pub-id-type="pmid">34850947</pub-id><pub-id pub-id-type="pmcid">PMC8728188</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>W. J.</given-names></name></person-group><article-title>BLAT&#8211;The BLAST-Like Alignment Tool</article-title><source><italic toggle="yes">Genome Research</italic></source><year>2002</year><volume>12</volume><issue>4</issue><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1101/gr.229202</pub-id><pub-id pub-id-type="pmid">11932250</pub-id><pub-id pub-id-type="pmcid">PMC187518</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C. T.</given-names></name></person-group><article-title>DEG: A Database of Essential Genes</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2004</year><volume>32</volume><issue>90001</issue><fpage>271D</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh024</pub-id><pub-id pub-id-type="pmid">14681410</pub-id><pub-id pub-id-type="pmcid">PMC308758</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoch</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Ciufo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Domrachev</surname><given-names>M.</given-names></name><etal/></person-group><article-title>NCBI Taxonomy: A Comprehensive Update on Curation</article-title><source><italic toggle="yes">Database</italic></source><year>2020</year><volume>2020</volume><pub-id pub-id-type="doi">10.1093/database/baaa062</pub-id><pub-id pub-id-type="publisher-id">baaa062</pub-id><pub-id pub-id-type="pmcid">PMC7408187</pub-id><pub-id pub-id-type="pmid">32761142</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doytchinova</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Flower</surname><given-names>D. R.</given-names></name></person-group><article-title>VaxiJen: A Server for Prediction of Protective Antigens, Tumour Antigens and Subunit Vaccines</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2007</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1471-2105-8-4</pub-id><pub-id pub-id-type="other">2-s2.0-33847031827</pub-id><pub-id pub-id-type="publisher-id">4</pub-id><pub-id pub-id-type="pmcid">PMC1780059</pub-id><pub-id pub-id-type="pmid">17207271</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#246;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Croning</surname><given-names>M. D. R.</given-names></name><name name-style="western"><surname>Apweiler</surname><given-names>R.</given-names></name></person-group><article-title>Evaluation of Methods for the Prediction of Membrane Spanning Regions</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2001</year><volume>17</volume><issue>7</issue><fpage>646</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/17.7.646</pub-id><pub-id pub-id-type="other">2-s2.0-0034899781</pub-id><pub-id pub-id-type="pmid">11448883</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnan</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kayala</surname><given-names>M. A.</given-names></name><etal/></person-group><article-title>High-Throughput Prediction of Protein Antigenicity Using Protein Microarray Data</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2010</year><volume>26</volume><issue>23</issue><fpage>2936</fpage><lpage>2943</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq551</pub-id><pub-id pub-id-type="other">2-s2.0-78449302373</pub-id><pub-id pub-id-type="pmid">20934990</pub-id><pub-id pub-id-type="pmcid">PMC2982151</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsirigos</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Damgaard Pedersen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>DeepTMHMM Predicts Alpha and Beta Transmembrane Proteins Using Deep Neural Networks</article-title><source><italic toggle="yes">BioRxiv</italic></source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.04.08.487609</pub-id></element-citation></ref><ref id="B54" content-type="article"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>Prediction of Continuous B-Cell Epitopes in an Antigen Using Recurrent Neural Network</article-title><source><italic toggle="yes">Proteins: Structure, Function, and Bioinformatics</italic></source><year>2006</year><volume>65</volume><issue>1</issue><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/prot.21078</pub-id><pub-id pub-id-type="other">2-s2.0-33748254730</pub-id><pub-id pub-id-type="pmid">16894596</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Overton</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>The Immune Epitope Database (IEDB): 2018 Update</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D339</fpage><lpage>D343</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1006</pub-id><pub-id pub-id-type="other">2-s2.0-85059798226</pub-id><pub-id pub-id-type="pmid">30357391</pub-id><pub-id pub-id-type="pmcid">PMC6324067</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>Generating Quantitative Models Describing the Sequence Specificity of Biological Processes With the Stabilized Matrix Method</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2005</year><volume>6</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1471-2105-6-132</pub-id><pub-id pub-id-type="other">2-s2.0-25444476693</pub-id><pub-id pub-id-type="publisher-id">132</pub-id><pub-id pub-id-type="pmcid">PMC1173087</pub-id><pub-id pub-id-type="pmid">15927070</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynisson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.</given-names></name></person-group><article-title>NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved Predictions of MHC Antigen Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted Ligand Data</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2020</year><volume>48</volume><issue>W1</issue><fpage>W449</fpage><lpage>W454</lpage><pub-id pub-id-type="doi">10.1093/NAR/GKAA379</pub-id><pub-id pub-id-type="pmid">32406916</pub-id><pub-id pub-id-type="pmcid">PMC7319546</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleri</surname><given-names>W.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhanda</surname><given-names>S. K.</given-names></name><etal/></person-group><article-title>The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fimmu.2017.00278</pub-id><pub-id pub-id-type="other">2-s2.0-85017247863</pub-id><pub-id pub-id-type="publisher-id">278</pub-id><pub-id pub-id-type="pmcid">PMC5348633</pub-id><pub-id pub-id-type="pmid">28352270</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stecher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Battistuzzi</surname><given-names>F. U.</given-names></name></person-group><article-title>MEGA11: Molecular Evolutionary Genetics Analysis Version 11</article-title><source><italic toggle="yes">Molecular Biology and Evolution</italic></source><year>2021</year><volume>38</volume><issue>7</issue><fpage>3022</fpage><lpage>3027</lpage><pub-id pub-id-type="doi">10.1093/molbev/msab120</pub-id><pub-id pub-id-type="pmid">33892491</pub-id><pub-id pub-id-type="pmcid">PMC8233496</pub-id></element-citation></ref><ref id="B60" content-type="article"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimitrov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bangov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Flower</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Doytchinova</surname><given-names>I.</given-names></name></person-group><article-title>AllerTOP v.2&#8211;A Server for in Silico Prediction of Allergens</article-title><source><italic toggle="yes">Journal of Molecular Modeling</italic></source><year>2014</year><volume>20</volume><issue>6</issue><pub-id pub-id-type="doi">10.1007/s00894-014-2278-5</pub-id><pub-id pub-id-type="other">2-s2.0-84901583210</pub-id><pub-id pub-id-type="publisher-id">2278</pub-id><pub-id pub-id-type="pmid">24878803</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Naorem</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>ToxinPred2: An Improved Method for Predicting Toxicity of Proteins</article-title><source><italic toggle="yes">Briefings in Bioinformatics</italic></source><year>2022</year><volume>23</volume><issue>5</issue><pub-id pub-id-type="doi">10.1093/bib/bbac174</pub-id><pub-id pub-id-type="publisher-id">bbac174</pub-id><pub-id pub-id-type="pmid">35595541</pub-id></element-citation></ref><ref id="B62" content-type="article"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhanda</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Vir</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raghava</surname><given-names>G. P. S.</given-names></name></person-group><article-title>Designing of Interferon-Gamma Inducing MHC Class-II Binders</article-title><source><italic toggle="yes">Biology Direct</italic></source><year>2013</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1745-6150-8-30</pub-id><pub-id pub-id-type="other">2-s2.0-84889053011</pub-id><pub-id pub-id-type="publisher-id">30</pub-id><pub-id pub-id-type="pmcid">PMC4235049</pub-id><pub-id pub-id-type="pmid">24304645</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Czerkinsky</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Svennerholm</surname><given-names>A. M.</given-names></name></person-group><article-title>Strategies for the Induction of Immune Responses at Mucosal Surfaces Making use of Cholera Toxin B Subunit as Immunogen, Carrier, and Adjuvant</article-title><source><italic toggle="yes">The American Journal of Tropical Medicine and Hygiene</italic></source><year>1994</year><volume>50</volume><issue>5 Suppl</issue><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">8203723</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stratmann</surname><given-names>T.</given-names></name></person-group><article-title>Cholera Toxin Subunit b as Adjuvant&#8212;an Accelerator in Protective Immunity and a Break in Autoimmunity</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2015</year><volume>3</volume><issue>3</issue><fpage>579</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.3390/vaccines3030579</pub-id><pub-id pub-id-type="other">2-s2.0-85016911331</pub-id><pub-id pub-id-type="pmid">26350596</pub-id><pub-id pub-id-type="pmcid">PMC4586468</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solanki</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>V.</given-names></name></person-group><article-title>Subtractive Proteomics to Identify Novel Drug Targets and Reverse Vaccinology for the Development of Chimeric Vaccine Against <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2018</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41598-018-26689-7</pub-id><pub-id pub-id-type="other">2-s2.0-85048561517</pub-id><pub-id pub-id-type="publisher-id">9044</pub-id><pub-id pub-id-type="pmcid">PMC5997985</pub-id><pub-id pub-id-type="pmid">29899345</pub-id></element-citation></ref><ref id="B66" content-type="article"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Construction of a Linker Library With Widely Controllable Flexibility for Fusion Protein Design</article-title><source><italic toggle="yes">Applied Microbiology and Biotechnology</italic></source><year>2016</year><volume>100</volume><issue>1</issue><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-6985-3</pub-id><pub-id pub-id-type="other">2-s2.0-84952985441</pub-id><pub-id pub-id-type="pmid">26394862</pub-id></element-citation></ref><ref id="B67" content-type="article"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kitayama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kamiya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagamune</surname><given-names>T.</given-names></name></person-group><article-title>Design of the Linkers Which Effectively Separate Domains of a Bifunctional Fusion Protein</article-title><source><italic toggle="yes">Protein Engineering Design and Selection</italic></source><year>2001</year><volume>14</volume><issue>8</issue><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1093/protein/14.8.529</pub-id><pub-id pub-id-type="pmid">11579220</pub-id></element-citation></ref><ref id="B68" content-type="article"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group><article-title>Vaccination With a Paramyosin-Based Multi-Epitope Vaccine Elicits Significant Protective Immunity Against <italic toggle="yes">Trichinella spiralis</italic> Infection in Mice</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fmicb.2017.01475</pub-id><pub-id pub-id-type="other">2-s2.0-85026842932</pub-id><pub-id pub-id-type="publisher-id">1475</pub-id><pub-id pub-id-type="pmcid">PMC5540943</pub-id><pub-id pub-id-type="pmid">28824599</pub-id></element-citation></ref><ref id="B69" content-type="article"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaro</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W. C.</given-names></name></person-group><article-title>Fusion Protein Linkers: Property, Design and Functionality</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2013</year><volume>65</volume><issue>10</issue><fpage>1357</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.039</pub-id><pub-id pub-id-type="other">2-s2.0-84881018686</pub-id><pub-id pub-id-type="pmid">23026637</pub-id><pub-id pub-id-type="pmcid">PMC3726540</pub-id></element-citation></ref><ref id="B70" content-type="incollection"><label>70</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Gasteiger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoogland</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gattiker</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protein Identification and Analysis Tools on the ExPASy Server</article-title><source><italic toggle="yes">The Proteomics Protocols Handbook</italic></source><year>2005</year><publisher-name>Humana Press</publisher-name><fpage>571</fpage><lpage>607</lpage></element-citation></ref><ref id="B71" content-type="article"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnan</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>P.</given-names></name></person-group><article-title>SOLpro: Accurate Sequence-Based Prediction of Protein Solubility</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2009</year><volume>25</volume><issue>17</issue><fpage>2200</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp386</pub-id><pub-id pub-id-type="other">2-s2.0-69949162927</pub-id><pub-id pub-id-type="pmid">19549632</pub-id></element-citation></ref><ref id="B72" content-type="article"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laskowski</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Jab&#322;o&#324;ska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pravda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Va&#345;ekov&#225;</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>J. M.</given-names></name></person-group><article-title>PDBsum: Structural Summaries of PDB Entries</article-title><source><italic toggle="yes">Protein Science</italic></source><year>2018</year><volume>27</volume><issue>1</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1002/pro.3289</pub-id><pub-id pub-id-type="other">2-s2.0-85039057623</pub-id><pub-id pub-id-type="pmid">28875543</pub-id><pub-id pub-id-type="pmcid">PMC5734310</pub-id></element-citation></ref><ref id="B73" content-type="article"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erdos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pajkos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doszt&#225;nyi</surname><given-names>Z.</given-names></name></person-group><article-title>IUPred3: Prediction of Protein Disorder Enhanced With Unambiguous Experimental Annotation and Visualization of Evolutionary Conservation</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2021</year><volume>49</volume><issue>W1</issue><fpage>W297</fpage><lpage>W303</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab408</pub-id><pub-id pub-id-type="pmid">34048569</pub-id><pub-id pub-id-type="pmcid">PMC8262696</pub-id></element-citation></ref><ref id="B74" content-type="article"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abramson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunger</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Accurate Structure Prediction of Biomolecular Interactions With AlphaFold 3</article-title><source><italic toggle="yes">Nature</italic></source><year>2024</year><volume>630</volume><issue>8016</issue><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07487-w</pub-id><pub-id pub-id-type="pmid">38718835</pub-id><pub-id pub-id-type="pmcid">PMC11168924</pub-id></element-citation></ref><ref id="B75" content-type="article"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seok</surname><given-names>C.</given-names></name></person-group><article-title>GalaxyRefine: Protein Structure Refinement Driven by Side-Chain Repacking</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2013</year><volume>41</volume><issue>W1</issue><fpage>W384</fpage><lpage>W388</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt458</pub-id><pub-id pub-id-type="other">2-s2.0-84883590772</pub-id><pub-id pub-id-type="pmid">23737448</pub-id><pub-id pub-id-type="pmcid">PMC3692086</pub-id></element-citation></ref><ref id="B76" content-type="article"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colovos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yeates</surname><given-names>T. O.</given-names></name></person-group><article-title>Verification of Protein Structures: Patterns of Nonbonded Atomic Interactions</article-title><source><italic toggle="yes">Protein Science</italic></source><year>1993</year><volume>2</volume><issue>9</issue><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1002/pro.5560020916</pub-id><pub-id pub-id-type="other">2-s2.0-0027180507</pub-id><pub-id pub-id-type="pmid">8401235</pub-id><pub-id pub-id-type="pmcid">PMC2142462</pub-id></element-citation></ref><ref id="B77" content-type="article"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiederstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sippl</surname><given-names>M. J.</given-names></name></person-group><article-title>ProSA-Web: Interactive Web Service for the Recognition of Errors in Three-Dimensional Structures of Proteins</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2007</year><volume>35</volume><issue>Web Server</issue><fpage>W407</fpage><lpage>W410</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm290</pub-id><pub-id pub-id-type="other">2-s2.0-34547566446</pub-id><pub-id pub-id-type="pmid">17517781</pub-id><pub-id pub-id-type="pmcid">PMC1933241</pub-id></element-citation></ref><ref id="B78" content-type="article"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Headd</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Moriarty</surname><given-names>N. W.</given-names></name><etal/></person-group><article-title>MolProbity: More and Better Reference Data for Improved All-Atom Structure Validation</article-title><source><italic toggle="yes">Protein Science</italic></source><year>2018</year><volume>27</volume><issue>1</issue><fpage>293</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1002/pro.3330</pub-id><pub-id pub-id-type="other">2-s2.0-85035199313</pub-id><pub-id pub-id-type="pmid">29067766</pub-id><pub-id pub-id-type="pmcid">PMC5734394</pub-id></element-citation></ref><ref id="B79" content-type="article"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lovell</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>I. W.</given-names></name><name name-style="western"><surname>Iii</surname><given-names>W. B. A.</given-names></name><etal/></person-group><article-title>Structure Validation by Calpha Geometry</article-title><source><italic toggle="yes">Proteins: Structure, Function, and Bioinformatics</italic></source><year>2003</year><volume>50</volume><issue>3</issue><fpage>437</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1002/prot.10286</pub-id><pub-id pub-id-type="other">2-s2.0-0037441653</pub-id><pub-id pub-id-type="pmid">12557186</pub-id></element-citation></ref><ref id="B80" content-type="article"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponomarenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>ElliPro: A New Structure-Based Tool for the Prediction of Antibody Epitopes</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2008</year><volume>9</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1471-2105-9-514</pub-id><pub-id pub-id-type="other">2-s2.0-58049187138</pub-id><pub-id pub-id-type="publisher-id">514</pub-id><pub-id pub-id-type="pmcid">PMC2607291</pub-id><pub-id pub-id-type="pmid">19055730</pub-id></element-citation></ref><ref id="B81" content-type="article"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>In Silico Analysis of Epitope-Based Vaccine Candidate against Tuberculosis Using Reverse Vaccinology</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2021</year><volume>11</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41598-020-80899-6</pub-id><pub-id pub-id-type="publisher-id">1249</pub-id><pub-id pub-id-type="pmcid">PMC7807040</pub-id><pub-id pub-id-type="pmid">33441913</pub-id></element-citation></ref><ref id="B82" content-type="article"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dombkowski</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>K. Z.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>D. B.</given-names></name></person-group><article-title>Protein Disulfide Engineering</article-title><source><italic toggle="yes">FEBS Letters</italic></source><year>2014</year><volume>588</volume><pub-id pub-id-type="doi">10.1016/j.febslet.2013.11.024</pub-id><pub-id pub-id-type="other">2-s2.0-84892371627</pub-id><pub-id pub-id-type="pmid">24291258</pub-id></element-citation></ref><ref id="B83" content-type="article"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craig</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Dombkowski</surname><given-names>A. A.</given-names></name></person-group><article-title>Disulfide by Design 2.0: A Web-Based Tool for Disulfide Engineering in Proteins</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2013</year><volume>14</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1471-2105-14-346</pub-id><pub-id pub-id-type="other">2-s2.0-84888312300</pub-id><pub-id pub-id-type="publisher-id">346</pub-id><pub-id pub-id-type="pmcid">PMC3898251</pub-id><pub-id pub-id-type="pmid">24289175</pub-id></element-citation></ref><ref id="B84" content-type="article"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dombkowski</surname><given-names>A. A.</given-names></name></person-group><article-title>Disulfide by Design&#8482;: A Computational Method for the Rational Design of Disulfide Bonds in Proteins</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2003</year><volume>19</volume><issue>14</issue><fpage>1852</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btg231</pub-id><pub-id pub-id-type="other">2-s2.0-0141506109</pub-id><pub-id pub-id-type="pmid">14512360</pub-id></element-citation></ref><ref id="B85" content-type="article"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teufel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Almagro Armenteros</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>A. R.</given-names></name><etal/></person-group><article-title>SignalP 6.0 Predicts All Five Types of Signal Peptides Using Protein Language Models</article-title><source><italic toggle="yes">Nature Biotechnology</italic></source><year>2022</year><volume>40</volume><issue>7</issue><fpage>1023</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1038/s41587-021-01156-3</pub-id><pub-id pub-id-type="pmcid">PMC9287161</pub-id><pub-id pub-id-type="pmid">34980915</pub-id></element-citation></ref><ref id="B86" content-type="article"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozakov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The ClusPro Web Server for Protein-Protein Docking</article-title><source><italic toggle="yes">Nature Protocols</italic></source><year>2017</year><volume>12</volume><issue>2</issue><fpage>255</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.169</pub-id><pub-id pub-id-type="other">2-s2.0-85010961048</pub-id><pub-id pub-id-type="pmid">28079879</pub-id><pub-id pub-id-type="pmcid">PMC5540229</pub-id></element-citation></ref><ref id="B87" content-type="article"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohto</surname><given-names>U.</given-names></name><name name-style="western"><surname>Fukase</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group><article-title>Structural Basis of Species-Specific Endotoxin Sensing by Innate Immune Receptor TLR4/MD-2</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2012</year><volume>109</volume><issue>19</issue><fpage>7421</fpage><lpage>7426</lpage><pub-id pub-id-type="doi">10.1073/pnas.1201193109</pub-id><pub-id pub-id-type="other">2-s2.0-84860832650</pub-id><pub-id pub-id-type="pmid">22532668</pub-id><pub-id pub-id-type="pmcid">PMC3358893</pub-id></element-citation></ref><ref id="B88" content-type="article"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burley</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>C.</given-names></name><etal/></person-group><article-title>RCSB Protein Data Bank: Sustaining a Living Digital Data Resource That Enables Breakthroughs in Scientific Research and Biomedical Education</article-title><source><italic toggle="yes">Protein Science</italic></source><year>2018</year><volume>27</volume><issue>1</issue><fpage>316</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1002/pro.3331</pub-id><pub-id pub-id-type="other">2-s2.0-85033564540</pub-id><pub-id pub-id-type="pmid">29067736</pub-id><pub-id pub-id-type="pmcid">PMC5734314</pub-id></element-citation></ref><ref id="B89" content-type="article"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hitzenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rieger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Zacharias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Im</surname><given-names>W.</given-names></name></person-group><article-title>CHARMM-GUI Supports the Amber Force Fields</article-title><source><italic toggle="yes">The Journal of Chemical Physics</italic></source><year>2020</year><volume>153</volume><issue>3</issue><pub-id pub-id-type="doi">10.1063/5.0012280</pub-id><pub-id pub-id-type="publisher-id">035103</pub-id><pub-id pub-id-type="pmid">32716185</pub-id></element-citation></ref><ref id="B90" content-type="article"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Fuglebakk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hollup</surname><given-names>S. M.</given-names></name><etal/></person-group><article-title>WEBnmat v2.0: Web Server and Services for Comparing Protein Flexibility</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2014</year><volume>15</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12859-014-0427-6</pub-id><pub-id pub-id-type="other">2-s2.0-84923868142</pub-id><pub-id pub-id-type="publisher-id">427</pub-id><pub-id pub-id-type="pmcid">PMC4339738</pub-id><pub-id pub-id-type="pmid">25547242</pub-id></element-citation></ref><ref id="B91" content-type="article"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Mackerell</surname><given-names>A. D.</given-names></name><etal/></person-group><article-title>CHARMM: The Biomolecular Simulation Program</article-title><source><italic toggle="yes">Journal of Computational Chemistry</italic></source><year>2009</year><volume>30</volume><issue>10</issue><fpage>1545</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1002/jcc.21287</pub-id><pub-id pub-id-type="other">2-s2.0-67650500988</pub-id><pub-id pub-id-type="pmid">19444816</pub-id><pub-id pub-id-type="pmcid">PMC2810661</pub-id></element-citation></ref><ref id="B92" content-type="article"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Swails</surname><given-names>J. M.</given-names></name><etal/></person-group><article-title>Pande, CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field</article-title><source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source><year>2016</year><volume>12</volume><issue>1</issue><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00935</pub-id><pub-id pub-id-type="other">2-s2.0-84955167919</pub-id><pub-id pub-id-type="pmid">26631602</pub-id><pub-id pub-id-type="pmcid">PMC4712441</pub-id></element-citation></ref><ref id="B93" content-type="article"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Giese</surname><given-names>T. J.</given-names></name><etal/></person-group><article-title>Alchemical Binding Free Energy Calculations in AMBER20: Advances and Best Practices for Drug Discovery</article-title><source><italic toggle="yes">Journal of Chemical Information and Modeling</italic></source><year>2020</year><volume>60</volume><issue>11</issue><fpage>5595</fpage><lpage>5623</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00613</pub-id><pub-id pub-id-type="pmid">32936637</pub-id><pub-id pub-id-type="pmcid">PMC7686026</pub-id></element-citation></ref><ref id="B94" content-type="article"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genheden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ryde</surname><given-names>U.</given-names></name></person-group><article-title>The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities</article-title><source><italic toggle="yes">Expert Opinion on Drug Discovery</italic></source><year>2015</year><volume>10</volume><issue>5</issue><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1517/17460441.2015.1032936</pub-id><pub-id pub-id-type="other">2-s2.0-84928313330</pub-id><pub-id pub-id-type="pmid">25835573</pub-id><pub-id pub-id-type="pmcid">PMC4487606</pub-id></element-citation></ref><ref id="B95" content-type="article"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vald&#233;s-Tresanco</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Vald&#233;s-Tresanco</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Valiente</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>E.</given-names></name></person-group><article-title>Gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations With GROMACS</article-title><source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source><year>2021</year><volume>17</volume><issue>10</issue><fpage>6281</fpage><lpage>6291</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.1c00645</pub-id><pub-id pub-id-type="pmid">34586825</pub-id></element-citation></ref><ref id="B96" content-type="article"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hawash</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F.</given-names></name></person-group><article-title>Strategies of Codon Optimization for High-Level Heterologous Protein Expression in Microbial Expression Systems</article-title><source><italic toggle="yes">Gene Reports</italic></source><year>2017</year><volume>9</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.genrep.2017.08.006</pub-id><pub-id pub-id-type="other">2-s2.0-85028708204</pub-id></element-citation></ref><ref id="B97" content-type="article"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madeira</surname><given-names>F.</given-names></name><name name-style="western"><surname>Madhusoodanan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The EMBL-EBI Job Dispatcher Sequence Analysis Tools Framework in 2024</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2024</year><volume>52</volume><issue>W1</issue><fpage>W521</fpage><lpage>W525</lpage><pub-id pub-id-type="doi">10.1093/nar/gkae241</pub-id><pub-id pub-id-type="pmid">38597606</pub-id><pub-id pub-id-type="pmcid">PMC11223882</pub-id></element-citation></ref><ref id="B98" content-type="misc"><label>98</label><element-citation publication-type="other"><collab>GenScript</collab><article-title>Codon Usage Frequency Table(chart)-Genscript</article-title><comment>GenScript</comment></element-citation></ref><ref id="B99" content-type="article"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamens</surname><given-names>J.</given-names></name></person-group><article-title>The Addgene Repository: An International Nonprofit Plasmid and Data Resource</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2015</year><volume>43</volume><issue>D1</issue><fpage>D1152</fpage><lpage>D1157</lpage><pub-id pub-id-type="doi">10.1093/nar/gku893</pub-id><pub-id pub-id-type="other">2-s2.0-84941081150</pub-id><pub-id pub-id-type="pmid">25392412</pub-id><pub-id pub-id-type="pmcid">PMC4384007</pub-id></element-citation></ref><ref id="B100" content-type="article"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbel</surname><given-names>M. J.</given-names></name></person-group><article-title>Brucellosis: An Overview</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>1997</year><volume>3</volume><issue>2</issue><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.3201/eid0302.970219</pub-id><pub-id pub-id-type="other">2-s2.0-0031111368</pub-id><pub-id pub-id-type="pmid">9204307</pub-id><pub-id pub-id-type="pmcid">PMC2627605</pub-id></element-citation></ref><ref id="B101" content-type="article"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>R.</given-names></name></person-group><article-title>Immunoinformatic-Guided Designing of Multi-Epitope Vaccine Construct Against Brucella Suis 1300</article-title><source><italic toggle="yes">Immunologic Research</italic></source><year>2023</year><volume>71</volume><issue>2</issue><fpage>247</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1007/s12026-022-09346-0</pub-id><pub-id pub-id-type="pmid">36459272</pub-id><pub-id pub-id-type="pmcid">PMC9716126</pub-id></element-citation></ref><ref id="B102" content-type="article"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraai</surname><given-names>I.</given-names></name><name name-style="western"><surname>Knoester</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bathoorn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nijland</surname><given-names>M.</given-names></name></person-group><article-title>Zoonotic Transmission of Vaccine-Derived <italic toggle="yes">Bordetella bronchiseptica</italic></article-title><source><italic toggle="yes">Open Forum Infectious Diseases</italic></source><year>2023</year><volume>10</volume><issue>8</issue><pub-id pub-id-type="doi">10.1093/ofid/ofad421</pub-id><pub-id pub-id-type="publisher-id">ofad421</pub-id><pub-id pub-id-type="pmcid">PMC10466264</pub-id><pub-id pub-id-type="pmid">37654786</pub-id></element-citation></ref><ref id="B103" content-type="article"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Basharat</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Vaccine Design From the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach</article-title><source><italic toggle="yes">Vaccines 95 - Molecular Approaches to the Control of Infectious Diseases</italic></source><year>2020</year><volume>8</volume><issue>3</issue><pub-id pub-id-type="doi">10.3390/vaccines8030423</pub-id><pub-id pub-id-type="publisher-id">423</pub-id><pub-id pub-id-type="pmcid">PMC7565012</pub-id><pub-id pub-id-type="pmid">32731461</pub-id></element-citation></ref><ref id="B104" content-type="article"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>K. M.</given-names></name><etal/></person-group><article-title>Landscape and Selection of Vaccine Epitopes in SARS-CoV-2</article-title><source><italic toggle="yes">Genome Medicine</italic></source><year>2021</year><volume>13</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s13073-021-00910-1</pub-id><pub-id pub-id-type="publisher-id">101</pub-id><pub-id pub-id-type="pmcid">PMC8201469</pub-id><pub-id pub-id-type="pmid">34127050</pub-id></element-citation></ref><ref id="B105" content-type="article"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naveed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tehreem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Design of a Novel Multiple Epitope-Based Vaccine: An Immunoinformatics Approach to Combat SARS-CoV-2 Strains</article-title><source><italic toggle="yes">Journal of Infection and Public Health</italic></source><year>2021</year><volume>14</volume><issue>7</issue><fpage>938</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2021.04.010</pub-id><pub-id pub-id-type="pmid">34119848</pub-id><pub-id pub-id-type="pmcid">PMC8093003</pub-id></element-citation></ref><ref id="B106" content-type="article"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulte</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Dilthey</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Klau</surname><given-names>G. W.</given-names></name></person-group><article-title>HOGVAX: Exploiting Epitope Overlaps to Maximize Population Coverage in Vaccine Design With Application to SARS-CoV-2</article-title><source><italic toggle="yes">Cell Systems</italic></source><year>2023</year><volume>14</volume><issue>12</issue><fpage>1122</fpage><lpage>1130.e3</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2023.11.001</pub-id><pub-id pub-id-type="pmid">38128484</pub-id></element-citation></ref><ref id="B107" content-type="article"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarvmeili</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baghban Kohnehrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gholizadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shanehbandi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ofoghi</surname><given-names>H.</given-names></name></person-group><article-title>Immunoinformatics Design of a Structural Proteins Driven Multi-Epitope Candidate Vaccine Against Different SARS-CoV-2 Variants Based on Fynomer</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2024</year><volume>14</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41598-024-61025-2</pub-id><pub-id pub-id-type="publisher-id">10297</pub-id><pub-id pub-id-type="pmcid">PMC11069592</pub-id><pub-id pub-id-type="pmid">38704475</pub-id></element-citation></ref><ref id="B108" content-type="article"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aiman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alhamhoom</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Multi-Epitope Chimeric Vaccine Design Against Emerging Monkeypox Virus Via Reverse Vaccinology Techniques- A Bioinformatics and Immunoinformatics Approach</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2022</year><volume>13</volume><pub-id pub-id-type="doi">10.3389/fimmu.2022.985450</pub-id><pub-id pub-id-type="publisher-id">985450</pub-id><pub-id pub-id-type="pmcid">PMC9452969</pub-id><pub-id pub-id-type="pmid">36091024</pub-id></element-citation></ref><ref id="B109" content-type="article"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behmard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soleymani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barzegari</surname><given-names>E.</given-names></name></person-group><article-title>Immunoinformatic Design of a COVID-19 Subunit Vaccine Using Entire Structural Immunogenic Epitopes of SARS-CoV-2</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2020</year><volume>10</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41598-020-77547-4</pub-id><pub-id pub-id-type="publisher-id">20864</pub-id><pub-id pub-id-type="pmcid">PMC7704662</pub-id><pub-id pub-id-type="pmid">33257716</pub-id></element-citation></ref><ref id="B110" content-type="article"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacchetta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gregori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roncarolo</surname><given-names>M. G.</given-names></name></person-group><article-title>CD4+ Regulatory T Cells: Mechanisms of Induction and Effector Function</article-title><source><italic toggle="yes">Autoimmunity Reviews</italic></source><year>2005</year><volume>4</volume><issue>8</issue><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2005.04.005</pub-id><pub-id pub-id-type="other">2-s2.0-26244448037</pub-id><pub-id pub-id-type="pmid">16214084</pub-id></element-citation></ref><ref id="B111" content-type="article"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arpin</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#233;chanet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Kooten</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Generation of Memory B Cells and Plasma Cells in Vitro</article-title><source><italic toggle="yes">Science</italic></source><year>1995</year><volume>268</volume><issue>5211</issue><fpage>720</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1126/science.7537388</pub-id><pub-id pub-id-type="other">2-s2.0-0029055061</pub-id><pub-id pub-id-type="pmid">7537388</pub-id></element-citation></ref><ref id="B112" content-type="article"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Youk</surname><given-names>S.</given-names></name><etal/></person-group><article-title>High Allelic Diversity of Dog Leukocyte Antigen Class II in East Asian Dogs: Identification of New Alleles and Haplotypes</article-title><source><italic toggle="yes">Journal of Mammalian Evolution</italic></source><year>2021</year><volume>28</volume><issue>3</issue><fpage>773</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1007/s10914-021-09560-x</pub-id></element-citation></ref><ref id="B113" content-type="article"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Blancher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inoko</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kulski</surname><given-names>J. K.</given-names></name></person-group><article-title>Comparative Genomics of the Human, Macaque and Mouse Major Histocompatibility Complex</article-title><source><italic toggle="yes">Immunology</italic></source><year>2017</year><volume>150</volume><issue>2</issue><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/imm.12624</pub-id><pub-id pub-id-type="other">2-s2.0-84978034173</pub-id><pub-id pub-id-type="pmid">27395034</pub-id><pub-id pub-id-type="pmcid">PMC5214800</pub-id></element-citation></ref><ref id="B114" content-type="article"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chawla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuspoca</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Akthar</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Immunoinformatics-Aided Rational Design of a Multi-Epitope Vaccine Targeting Feline Infectious Peritonitis Virus</article-title><source><italic toggle="yes">Frontiers in Veterinary Science</italic></source><year>2023</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fvets.2023.1280273</pub-id><pub-id pub-id-type="publisher-id">1280273</pub-id><pub-id pub-id-type="pmcid">PMC10773687</pub-id><pub-id pub-id-type="pmid">38192725</pub-id></element-citation></ref><ref id="B115" content-type="article"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyamae</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishiya</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Haplotype Structures and Polymorphisms of Dog Leukocyte Antigen (DLA) Class I Loci Shaped by Intralocus and Interlocus Recombination Events</article-title><source><italic toggle="yes">Immunogenetics</italic></source><year>2022</year><volume>74</volume><issue>2</issue><fpage>245</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/s00251-021-01234-5</pub-id><pub-id pub-id-type="pmid">34993565</pub-id></element-citation></ref><ref id="B116" content-type="article"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyamae</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katakura</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kulski</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Moritomo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiina</surname><given-names>T.</given-names></name></person-group><article-title>Large-Scale Polymorphism Analysis of Dog Leukocyte Antigen Class I and Class II Genes (DLA-88, DLA-12/88L and DLA-DRB1) and Comparison of the Haplotype Diversity Between Breeds in Japan</article-title><source><italic toggle="yes">Cells</italic></source><year>2023</year><volume>12</volume><issue>5</issue><pub-id pub-id-type="doi">10.3390/cells12050809</pub-id><pub-id pub-id-type="publisher-id">809</pub-id><pub-id pub-id-type="pmcid">PMC10001263</pub-id><pub-id pub-id-type="pmid">36899945</pub-id></element-citation></ref><ref id="B117" content-type="article"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakazawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyamae</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Dog Leukocyte Antigen (DLA) Class II Genotypes Associated With Chronic Enteropathy in French Bulldogs and Miniature Dachshunds</article-title><source><italic toggle="yes">Veterinary Immunology and Immunopathology</italic></source><year>2021</year><volume>237</volume><pub-id pub-id-type="doi">10.1016/j.vetimm.2021.110271</pub-id><pub-id pub-id-type="publisher-id">110271</pub-id><pub-id pub-id-type="pmid">34044267</pub-id></element-citation></ref><ref id="B118" content-type="article"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>D.</given-names></name><name name-style="western"><surname>Katakura</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Dog Leukocyte Antigen Class II Alleles and Haplotypes Associated With Meningoencephalomyelitis of Unknown Origin in Chihuahuas</article-title><source><italic toggle="yes">Journal of Veterinary Medical Science</italic></source><year>2023</year><volume>85</volume><issue>1</issue><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1292/jvms.22-0116</pub-id><pub-id pub-id-type="pmid">36418080</pub-id><pub-id pub-id-type="pmcid">PMC9887217</pub-id></element-citation></ref><ref id="B119" content-type="article"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaech</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Memory CD8+ T Cell Differentiation: Initial Antigen Encounter Triggers a Developmental Program in Na&#239;ve Cells</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2001</year><volume>2</volume><issue>5</issue><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/87720</pub-id><pub-id pub-id-type="pmid">11323695</pub-id><pub-id pub-id-type="pmcid">PMC3760150</pub-id></element-citation></ref><ref id="B120" content-type="article"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shamriz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ofoghi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moazami</surname><given-names>N.</given-names></name></person-group><article-title>Effect of Linker Length and Residues on the Structure and Stability of a Fusion Protein With Malaria Vaccine Application</article-title><source><italic toggle="yes">Computers in Biology and Medicine</italic></source><year>2016</year><volume>76</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2016.06.015</pub-id><pub-id pub-id-type="other">2-s2.0-84977603692</pub-id><pub-id pub-id-type="pmid">27393958</pub-id></element-citation></ref><ref id="B121" content-type="article"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orbegozo-Medina</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Sern&#225;ndez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Folgueira</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Antibody Responses to Chimeric Peptides Derived From Parasite Antigens in Mice and Other Animal Species</article-title><source><italic toggle="yes">Molecular Immunology</italic></source><year>2019</year><volume>106</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2018.11.019</pub-id><pub-id pub-id-type="other">2-s2.0-85058435329</pub-id><pub-id pub-id-type="pmid">30572282</pub-id></element-citation></ref><ref id="B122" content-type="article"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M. T.</given-names></name></person-group><article-title>Recent Advances of Vaccine Adjuvants for Infectious Diseases</article-title><source><italic toggle="yes">Immune Network</italic></source><year>2015</year><volume>15</volume><issue>2</issue><pub-id pub-id-type="doi">10.4110/in.2015.15.2.51</pub-id><pub-id pub-id-type="publisher-id">51</pub-id><pub-id pub-id-type="pmcid">PMC4411509</pub-id><pub-id pub-id-type="pmid">25922593</pub-id></element-citation></ref><ref id="B123" content-type="article"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraser</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Altreuter</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Ilyinskii</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Generation of a Universal CD4 Memory T Cell Recall Peptide Effective in Humans, Mice and Non-Human Primates</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2014</year><volume>32</volume><issue>24</issue><fpage>2896</fpage><lpage>2903</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.024</pub-id><pub-id pub-id-type="other">2-s2.0-84899953855</pub-id><pub-id pub-id-type="pmid">24583006</pub-id></element-citation></ref><ref id="B124" content-type="article"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yahaya</surname><given-names>M. A. F.</given-names></name><name name-style="western"><surname>Bakar</surname><given-names>A. R. A.</given-names></name><name name-style="western"><surname>Stanslas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nordin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zainol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mehat</surname><given-names>M. Z.</given-names></name></person-group><article-title>Insights from Molecular Docking and Molecular Dynamics on the Potential of Vitexin as an Antagonist Candidate Against Lipopolysaccharide (LPS) for Microglial Activation in Neuroinflammation</article-title><source><italic toggle="yes">BMC Biotechnology</italic></source><year>2021</year><volume>21</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12896-021-00697-4</pub-id><pub-id pub-id-type="publisher-id">38</pub-id><pub-id pub-id-type="pmcid">PMC8178909</pub-id><pub-id pub-id-type="pmid">34090414</pub-id></element-citation></ref><ref id="B125" content-type="article"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francisco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Billod</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Merino</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Induction of TLR4/TLR2 Interaction and Heterodimer Formation by Low Endotoxic Atypical LPS</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2022</year><volume>12</volume><pub-id pub-id-type="doi">10.3389/fimmu.2021.748303</pub-id><pub-id pub-id-type="publisher-id">748303</pub-id><pub-id pub-id-type="pmcid">PMC8818788</pub-id><pub-id pub-id-type="pmid">35140704</pub-id></element-citation></ref><ref id="B126" content-type="article"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narsaria</surname><given-names>U.</given-names></name><name name-style="western"><surname>Basak</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Candidate Multi-Epitope Vaccine Against SARS-CoV-2</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2020</year><volume>10</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41598-020-67749-1</pub-id><pub-id pub-id-type="publisher-id">10895</pub-id><pub-id pub-id-type="pmcid">PMC7331818</pub-id><pub-id pub-id-type="pmid">32616763</pub-id></element-citation></ref><ref id="B127" content-type="article"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashidian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gandabeh</surname><given-names>Z. S.</given-names></name><name name-style="western"><surname>Forouharmehr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nazifi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shams</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaydari</surname><given-names>A.</given-names></name></person-group><article-title>Immunoinformatics Approach to Engineer a Potent Poly-Epitope Fusion Protein Vaccine Against <italic toggle="yes">Coxiella burnetii</italic></article-title><source><italic toggle="yes">International Journal of Peptide Research and Therapeutics</italic></source><year>2020</year><volume>26</volume><issue>4</issue><fpage>2191</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1007/s10989-019-10013-6</pub-id></element-citation></ref><ref id="B128" content-type="article"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shams</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nourmohammadi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Majidiani</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Engineering a Multi-Epitope Vaccine Candidate Against Leishmania Infantum Using Comprehensive Immunoinformatics Methods</article-title><source><italic toggle="yes">Biologia</italic></source><year>2022</year><volume>77</volume><issue>1</issue><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1007/s11756-021-00934-3</pub-id><pub-id pub-id-type="pmid">34866641</pub-id><pub-id pub-id-type="pmcid">PMC8628819</pub-id></element-citation></ref><ref id="B129" content-type="article"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsowayeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Albutti</surname><given-names>A.</given-names></name></person-group><article-title>Designing a Novel Chimeric Multi-Epitope Vaccine against <italic toggle="yes">Burkholderia pseudomallei</italic>, A Causative Agent of Melioidosis</article-title><source><italic toggle="yes">Frontiers in Medicine</italic></source><year>2022</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmed.2022.945938</pub-id><pub-id pub-id-type="publisher-id">945938</pub-id><pub-id pub-id-type="pmcid">PMC9623267</pub-id><pub-id pub-id-type="pmid">36330071</pub-id></element-citation></ref><ref id="B130" content-type="article"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sen Gupta</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group><article-title>Cell Surface Fibroblast Activation Protein-2 (Fap2) of <italic toggle="yes">Fusobacterium nucleatum</italic> as a Vaccine Candidate for Therapeutic Intervention of Human Colorectal Cancer: An Immunoinformatics Approach</article-title><source><italic toggle="yes">Vaccines 95&#8211;Molecular Approaches to the Control of Infectious Diseases</italic></source><year>2023</year><volume>11</volume><issue>3</issue><pub-id pub-id-type="doi">10.3390/vaccines11030525</pub-id><pub-id pub-id-type="publisher-id">525</pub-id><pub-id pub-id-type="pmcid">PMC10056511</pub-id><pub-id pub-id-type="pmid">36992108</pub-id></element-citation></ref><ref id="B131" content-type="article"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashemzadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>nezhad</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Khoshkhabar</surname><given-names>H.</given-names></name></person-group><article-title>Immunoinformatics Analysis of <italic toggle="yes">Brucella melitensis</italic> to Approach a Suitable Vaccine Against Brucellosis</article-title><source><italic toggle="yes">Journal of Genetic Engineering and Biotechnology</italic></source><year>2023</year><volume>21</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s43141-023-00614-6</pub-id><pub-id pub-id-type="publisher-id">152</pub-id><pub-id pub-id-type="pmcid">PMC10686926</pub-id><pub-id pub-id-type="pmid">38019359</pub-id></element-citation></ref><ref id="B132" content-type="article"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vishnu</surname><given-names>U. S.</given-names></name><name name-style="western"><surname>Sankarasubramanian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gunasekaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rajendhran</surname><given-names>J.</given-names></name></person-group><article-title>Identification of Potential Antigens From Non-Classically Secreted Proteins and Designing Novel Multitope Peptide Vaccine Candidate Against <italic toggle="yes">Brucella melitensis</italic> Through Reverse Vaccinology and Immunoinformatics Approach</article-title><source><italic toggle="yes">Infection, Genetics and Evolution</italic></source><year>2017</year><volume>55</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.09.015</pub-id><pub-id pub-id-type="other">2-s2.0-85029524928</pub-id><pub-id pub-id-type="pmid">28919551</pub-id></element-citation></ref><ref id="B133" content-type="article"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A Multi-Epitope Subunit Vaccine Based on CU/ZN-SOD, OMP31 and BP26 Against <italic toggle="yes">Brucella melitensis</italic> Infection in BALB/C Mice</article-title><source><italic toggle="yes">International Immunopharmacology</italic></source><year>2024</year><volume>127</volume><pub-id pub-id-type="doi">10.1016/j.intimp.2023.111351</pub-id><pub-id pub-id-type="publisher-id">111351</pub-id><pub-id pub-id-type="pmid">38113688</pub-id></element-citation></ref><ref id="B134" content-type="article"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Design of a New Multi-Epitope Vaccine Against Brucella Based on T and B Cell Epitopes Using Bioinformatics Methods</article-title><source><italic toggle="yes">Epidemiology and Infection</italic></source><year>2021</year><volume>149</volume><pub-id pub-id-type="doi">10.1017/S0950268821001229</pub-id><pub-id pub-id-type="publisher-id">e136</pub-id><pub-id pub-id-type="pmcid">PMC8220514</pub-id><pub-id pub-id-type="pmid">34032200</pub-id></element-citation></ref><ref id="B135" content-type="article"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Haimiti</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Bioinformatics-Based Design of a Fusion Vaccine With CTLA-4 Variable Region to Combat Brucella</article-title><source><italic toggle="yes">Brazilian Journal of Medical and Biological Research</italic></source><year>2023</year><volume>56</volume><pub-id pub-id-type="doi">10.1590/1414-431x2023e12938</pub-id><pub-id pub-id-type="publisher-id">e12938</pub-id><pub-id pub-id-type="pmcid">PMC10361638</pub-id><pub-id pub-id-type="pmid">37493775</pub-id></element-citation></ref><ref id="B136" content-type="article"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Bioinformatics Analysis of Omp19 and Omp25 Proteins for Designing Multi-Epitope Vaccines Against Brucella</article-title><source><italic toggle="yes">Medicine (United States)</italic></source><year>2023</year><volume>102</volume><issue>11</issue><pub-id pub-id-type="doi">10.1097/MD.0000000000033182</pub-id><pub-id pub-id-type="publisher-id">e33182</pub-id><pub-id pub-id-type="pmcid">PMC10019172</pub-id><pub-id pub-id-type="pmid">36930131</pub-id></element-citation></ref><ref id="B137" content-type="article"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hisham</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ashhab</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of Cross-Protective Potential Antigens Against Pathogenic <italic toggle="yes">Brucella</italic> spp. Through Combining Pan-Genome Analysis With Reverse Vaccinology</article-title><source><italic toggle="yes">Journal of Immunology Research</italic></source><year>2018</year><volume>2018</volume><pub-id pub-id-type="doi">10.1155/2018/1474517</pub-id><pub-id pub-id-type="other">2-s2.0-85059798385</pub-id><pub-id pub-id-type="publisher-id">1474517</pub-id><pub-id pub-id-type="pmcid">PMC6304850</pub-id><pub-id pub-id-type="pmid">30622973</pub-id></element-citation></ref><ref id="B138" content-type="article"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Demneh</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>B.</given-names></name><etal/></person-group><article-title>In Silico Design of a Novel Multi-Epitope Vaccine Against HCV Infection Through Immunoinformatics Approaches</article-title><source><italic toggle="yes">International Journal of Biological Macromolecules</italic></source><year>2024</year><volume>267</volume><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.131517</pub-id><pub-id pub-id-type="publisher-id">131517</pub-id><pub-id pub-id-type="pmid">38621559</pub-id></element-citation></ref><ref id="B139" content-type="article"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An In Silico Multi-Epitopes Vaccine Ensemble and Characterization Against Nosocomial <italic toggle="yes">Proteus penneri</italic></article-title><source><italic toggle="yes">Molecular Biotechnology</italic></source><year>2024</year><volume>66</volume><issue>12</issue><fpage>3498</fpage><lpage>3513</lpage><pub-id pub-id-type="doi">10.1007/s12033-023-00949-y</pub-id><pub-id pub-id-type="pmid">37934390</pub-id></element-citation></ref><ref id="B140" content-type="article"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nazarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Computational Design of a Multi-Epitope Vaccine Candidate Against Langya Henipavirus Using Surface Proteins</article-title><source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source><year>2023</year><volume>42</volume><issue>20</issue><fpage>10617</fpage><lpage>10634</lpage><pub-id pub-id-type="doi">10.1080/07391102.2023.2258403</pub-id><pub-id pub-id-type="pmid">37713338</pub-id></element-citation></ref><ref id="B141" content-type="article"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saldanha</surname><given-names>L.</given-names></name><name name-style="western"><surname>Langel</surname><given-names>&#220;.</given-names></name><name name-style="western"><surname>Vale</surname><given-names>N.</given-names></name></person-group><article-title>In Silico Studies to Support Vaccine Development</article-title><source><italic toggle="yes">Pharmaceutics</italic></source><year>2023</year><volume>15</volume><issue>2</issue><pub-id pub-id-type="doi">10.3390/pharmaceutics15020654</pub-id><pub-id pub-id-type="publisher-id">654</pub-id><pub-id pub-id-type="pmcid">PMC9963741</pub-id><pub-id pub-id-type="pmid">36839975</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Workflow diagram of the current study illustrating the sequential use of proteomics and reverse vaccinology techniques in designing the multiepitope vaccine for <italic toggle="yes">B. canis</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Quantitative representation of the subcellular localization of <italic toggle="yes">B. canis</italic> proteins as predicted by the PSORTb server.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.002.jpg"/></fig><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>B- and T-cell epitopes predicted using ABCPred and IEDB.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.003.jpg"/></fig><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>The predicted overlapping epitopes, antigenicity, allergenicity, toxicity, and potential interferon-gamma inducing.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.004.jpg"/></fig><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Design and structural modeling of the multiepitope vaccine against <italic toggle="yes">B. canis</italic>. (A) Order of binding for the predicted overlapping antigenic epitopes and their adjacent adjuvant sequences. (B) The sequence of the multiepitope vaccine. (C) Refined 3D structure of the prioritized vaccine construct.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.005.jpg"/></fig><fig position="float" id="fig6" orientation="portrait"><label>Figure 6</label><caption><p>The secondary structure prediction of the vaccine design as performed by the PSIPRED server.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.006.jpg"/></fig><fig position="float" id="fig7" orientation="portrait"><label>Figure 7</label><caption><p>Structural assessment of the multiepitope vaccine construct for <italic toggle="yes">B. canis</italic>. (A) Ramachandran plot: Ramachandran plot statistics display 97.2% of residues within the most favorable regions and 2.8% in allowed regions. (B) Overall model quality from ProSA-web analysis showing a <italic toggle="yes">Z</italic>-score of &#8722;4.95 and (C) local model quality for the prioritized vaccine construct.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.007.jpg"/></fig><fig position="float" id="fig8" orientation="portrait"><label>Figure 8</label><caption><p>Representation of the molecular docking complex between chimeric multiepitope vaccine and Toll-like receptor 4 (TLR4) complex. (A) Three-dimensional visualization of the docking complex of the vaccine construct (in red) with <italic toggle="yes">M. musculus</italic> TLR4/MD-2/lipid IVa complex (in purpure). (B) Molecular interactions between chain A of the TLR4 receptor molecule and chain B of the vaccine construct and (C) interactions between chain B and chain C of the TLR4/MD-2/lipid IVa complex. (D) Hydrogen-bond interactions between chains A and B, and chains B and C.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.008.jpg"/></fig><fig position="float" id="fig9" orientation="portrait"><label>Figure 9</label><caption><p>Assessment of the dynamic stability and residual flexibility of the modeled vaccine&#8211;Toll-like receptor 4 (TLR4) complex. (A) Root mean square deviation (RMSD) plot of the vaccine construct. (B) Radius of gyration (Rgyr) plot of the vaccine construct. (C) Root mean square fluctuation (RMSF) plot of the vaccine construct. (D) RMSD plot of the vaccine-TLR4 complex. (E) Rgyr plot of the vaccine-TLR4 complex. (F) RMSF plot of the vaccine&#8211;TLR4 complex.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.009.jpg"/></fig><fig position="float" id="fig10" orientation="portrait"><label>Figure 10</label><caption><p>Normal mode analysis of the vaccine&#8211;Toll-like receptor 4 (TLR4) complex. (A) Eigenvalues for the 50 modes with the lowest frequencies. (B) Average deformation energies for the 14 modes with the lowest frequencies. (C) Covariance matrix illustrating the mobility correlations between residues pairs with the complex. (D) Fluctuation plot of the low-frequency modes. (E) Plot of atomic displacements associated with the low-frequency modes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.010.jpg"/></fig><fig position="float" id="fig11" orientation="portrait"><label>Figure 11</label><caption><p>(A) In silico cloning of the vaccine construct sequence into the pET-28a (+) expression vector. The construct sequence (blue) was cloned between the vector's <italic toggle="yes">EcoRI</italic> and <italic toggle="yes">BamHI</italic> restriction sites (black). (B) 1% agarose gel electrophoresis simulation. The lanes show the molecular weight (MW), and the cloning results in positions 1&#8211;3, where lane 1, lane 2, and lane 3 represent the vaccine construct (888bp), the pET-28a (+) (5369bp), and the recombinant plasmid (6245bp), respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2025-6348238.011.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of the potential proteins for developing of the multiepitope vaccine for <italic toggle="yes">B. canis</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Protein name</th><th align="center" rowspan="1" colspan="1">PSORTb results</th><th align="center" rowspan="1" colspan="1">Molecular weight (kDa)</th><th align="center" rowspan="1" colspan="1">Transmembrane helices</th><th align="center" rowspan="1" colspan="1">Topology</th><th align="center" rowspan="1" colspan="1">Antigenicity VaxiJen</th><th align="center" rowspan="1" colspan="1">Antigenicity ANTIGENpro</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004684587.1">WP_004684587.1</ext-link> MetQ/NlpA family ABC transporter substrate-binding protein</td><td align="center" rowspan="1" colspan="1">Cytoplasmic membrane</td><td align="center" rowspan="1" colspan="1">27.97</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Globular + signal peptide</td><td align="center" rowspan="1" colspan="1">0.4340 Probable antigen</td><td align="center" rowspan="1" colspan="1">0.751838 Probable antigen</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004690079.1">WP_004690079.1</ext-link> Nitrate reductase subunit beta</td><td align="center" rowspan="1" colspan="1">Cytoplasmic membrane</td><td align="center" rowspan="1" colspan="1">58.14</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Globular</td><td align="center" rowspan="1" colspan="1">0.5512 Probable antigen</td><td align="center" rowspan="1" colspan="1">0.824488 Probable antigen</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_004692008.1">WP_004692008.1</ext-link> Bifunctional diguanylate cyclase/phosphodiesterase</td><td align="center" rowspan="1" colspan="1">Cytoplasmic membrane</td><td align="center" rowspan="1" colspan="1">78.88</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Globular</td><td align="center" rowspan="1" colspan="1">0.4321 Probable antigen</td><td align="center" rowspan="1" colspan="1">0.099321 Probable not antigen</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WP_006133077.1">WP_006133077.1</ext-link> Autotransporter adhesin BtaE</td><td align="center" rowspan="1" colspan="1">Outer membrane</td><td align="center" rowspan="1" colspan="1">75.53</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">0.7680 Probable antigen</td><td align="center" rowspan="1" colspan="1">0.883782 Probable antigen</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>The properties of the multiepitope protein.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Tool/parameter</th><th align="center" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of amino acids</td><td align="center" rowspan="1" colspan="1">289</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecular weight (Daltons)</td><td align="center" rowspan="1" colspan="1">30.3 kDa</td></tr><tr><td align="left" rowspan="1" colspan="1">Theoretical pI</td><td align="center" rowspan="1" colspan="1">9.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Instability index</td><td align="center" rowspan="1" colspan="1">30.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Aliphatic index</td><td align="center" rowspan="1" colspan="1">84.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydropathicity GRAVY</td><td align="center" rowspan="1" colspan="1">&#8722;0.117</td></tr><tr><td align="left" rowspan="1" colspan="1">SoLpro</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Antigenicity (Vaxijen score)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Antigenicity (ANTIGENpro)</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Allergenicity</td><td align="center" rowspan="1" colspan="1">Nonallergen</td></tr><tr><td align="left" rowspan="1" colspan="1">Toxicity</td><td align="center" rowspan="1" colspan="1">Nontoxic</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Discontinuous B-cell epitopes of vaccine construct.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">Residues</th><th align="center" rowspan="1" colspan="1">No. of residues</th><th align="center" rowspan="1" colspan="1">ElliPro score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">A:K180, A:V181, A:E182, A:R183, A:D185, A:G186, A:T187, A:S188</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0.935</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">A:V129, A:G130, A:V131, A:T132, A:P133, A:G134, A:S135, A:G136, A:S137, A:K138, A:P139, A:V140, A:I141, A:S142, A:A143, A:E145, A:R146</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">A:T118, A:A119, A:G120, A:S121, A:A122, A:F123, A:A124, A:K125, A:T126, A:L127, A:R128</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">A:G228, A:S229, A:G230, A:S231, A:T232, A:V233, A:S234, A:V235, A:G236, A:D237, A:K238, A:G239, A:A240, A:E241, A:R242, A:T243, A:I244, A:T245, A:N246, A:V247</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">0.754</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">A:A149, A:M150, A:Y153, A:G154, A:S155, A:G156, A:S157, A:Y158, A:V159, A:P160, A:P161, A:L162, A:S163, A:P164, A:L165, A:Q166, A:S167, A:A168, A:A169, A:Q170, A:A171, A:G172, A:K173, A:G174, A:S175, A:G176, A:S177, A:E178, A:R179, A:R189, A:T190, A:M191, A:R192, A:I193, A:I194</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">A:I271, A:G272, A:I273, A:P274, A:M275, A:G276, A:L277, A:P278, A:Q279, A:S280, A:I281, A:A282, A:L283, A:S284, A:S285, A:V287, A:A288, A:Q289</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0.709</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">A:H14, A:N15, A:N90, A:N91, A:K92, A:T93, A:P94</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0.627</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">A:K195, A:S196, A:S197, A:I198, A:P199, A:P200, A:V201, A:E202, A:G203, A:N204, A:E205, A:G206</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.621</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">A:A33, A:G34, A:K35, A:R36</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">A:V210, A:N211, A:V212, A:S213, A:K216</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0.556</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">A:G55, A:S56, A:Q57, A:H58</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0.507</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab4" orientation="portrait"><label>Table 4</label><caption><p>Estimated binding-free energy for the vaccine construct&#8211;TLR4 complex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Energy contributions</th><th align="center" rowspan="1" colspan="1">Vaccine construct&#8211;TLR4 complex (kcal/mol)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Van de Waals energy</td><td align="center" rowspan="1" colspan="1">&#8722;402.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Electrostatic energy</td><td align="center" rowspan="1" colspan="1">&#8722;2194.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Gas phase energy</td><td align="center" rowspan="1" colspan="1">&#8722;2597.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Solvation energy</td><td align="center" rowspan="1" colspan="1">2321.24</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>